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ABSTRACT
TYPE 2 DIABETES MELLITUS (T2DM)
ONSET AND “REMISSION”

Srikanth Tangelloju
July 20, 2016
Background
Type 2 diabetes mellitus (T2DM) is a progressive disease
condition. As the disease progresses the function of beta (β) cells (cells
which regulate insulin) decline, thereby increasing the circulating blood
glucose levels. If left unmanaged the disease progresses from onset to
development of T2DM related complications and eventually death. When
managed, in certain individuals, T2DM onset can be prevented and/or
slowed down and in certain T2DM individuals, remission is observed.
There are some known modifiable risk factors such as diet and physical
activities that are associated with the speed and direction of progression,
but much is still unknown. In order to develop effective intervention and
management programs, it is first important to understand the factors that
predict speed and direction of T2DM progression.
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Purpose
This dissertation evaluated T2DM disease progression with three
key objectives: a) evaluate factors that predict T2DM onset; b) evaluate
rate of T2DM “remission” and, c) evaluate factors that predict T2DM
“remission” in Medicare patients 65 years and older who did not undergo
bariatric surgery.
Methods
A retrospective cohort analysis of a Medicare Advantage health
plan was conducted using administrative data. An individual was identified
as T2DM if they had: ≥ 2 medical claims for T2DM coded 250.xx excluding
type 1 diabetes; or ≥ 2 pharmacy claims related to T2DM; or ≥ 2 combined
medical claims, pharmacy claims for T2DM in 12 months. A T2DM
individual was in “remission” if they had no T2DM related claims for more
than 12 months continuously. This is different from the standard American
Diabetes Association definition of remission which includes HbA1c values
and hence is represented in quotation (as “remission”). 89,390 individuals
were evaluated for T2DM onset and 10,059 T2DM individuals were
evaluated for T2DM “remission” over a period of 8 years from 2008 to
2015. Cox proportional hazards was used to identify significant variables
associated with T2DM onset and “remission.”
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Results
The factors that were significantly associated with T2DM onset
were: male gender; non-white ethnicity (African American, Hispanics);
statin use; hypertension; hyperlipidemia; heart failure; ulcer of lower limbs;
atherosclerosis; other retinopathy; angina pectoris; blindness and low
vision; absence of other chronic ischemic heart disease (IHD) (p<0.05).
T2DM “remission” does occur without bariatric surgery. 4.97%
(95% CI, 3.05% - 8.00%) of Medicare Patients 65 years and older met the
definition of T2DM “remission” in the study cohort.
The factors associated with T2DM “remission” were no statin use;
low diabetes complications severity index score (DCSI); no hypertension;
no hyperlipidemia; no neuropathy; no retinopathy (p<0.05). Race
(Asian/Hispanic). Other chronic ischemic heart disease (IHD) and female
gender were significantly associated with T2DM “remission” (p<0.05).
Conclusions
In line with previously published studies, the study presented here
also found that hyperlipidemia, hypertension, gender and race are
significantly associated with T2DM onset. In addition to these known
factors, this study identified additional factors associated with T2DM onset
such as: statin use; hypertension; hyperlipidemia; heart failure; ulcer of
lower limbs; atherosclerosis; other retinopathy; angina pectoris; blindness
and low vision and absence of other chronic ischemic heart disease.
vii

This study found that in Medicare T2DM patients 65 years and
older “remission” does occur without bariatric surgery. This study verified
known factors such as absence of dyslipidemia and race to be associated
with T2DM “remission.” In addition to these known factors this study found
that no statin use; low diabetes complications severity index score (DCSI);
no hypertension; no neuropathy; no retinopathy; presence of other chronic
ischemic heart disease (IHD) and female gender were significantly
associated with T2DM “remission.”
These findings could be used for the development of T2DM related
disease intervention and management programs. The DCSI score of
T2DM individuals could be used to help stratify them based on T2DM
severity for design and individualized, targeted outreach.
Lastly, in this study hypertension, hyperlipidemia, statins use were
associated with T2DM onset and T2DM “remission.” Since these factors
are also associated with metabolic disease, their mutual relation needs to
be evaluated further, upon availability of laboratory and physician notes
data. Metabolic disease is a known predictor for T2DM onset and future
studies might find that metabolic disease might also be a predictor for
T2DM “remission.”
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INTRODUCTION
Background to the study
Type 2 Diabetes Mellitus (T2DM) is a chronic condition wherein the beta cells
in the body do not produce enough insulin – a hormone that regulates blood
sugar – or the body does not use insulin well enough (also called insulin
resistance), or there is complete absence of insulin production. T2DM is
associated with deleterious macro- and microvascular outcomes (1, 2) and is the
leading cause of significant morbidities such as kidney failure, lower limb
amputations, blindness (3). T2DM is the seventh leading cause of death in the
United States and affects 29.1 million people (4). The total estimated national
cost of diabetes in the United States in 2012 was more than $245 billion, up from
$174 billion in 2007 (5).
T2DM is a progressive disease condition. If left unmanaged the T2DM
progresses from onset (first occurrence of T2DM) to development of T2DM
related complications and eventually death. However, when properly managed,
in certain individuals the T2DM disease progression can be slowed down and in
certain individuals T2DM “remission” is observed (i.e., no T2DM symptoms after
onset – detailed definitions below in the literature review section below).
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Even though there is some available literature on factors associated with
T2DM onset and “remission” there is a lot of opportunity to further understand
these factors, especially in the Medicare population who are 65 years or older.
Understanding the factors that impact T2DM disease progression is important
because it will help in designing efficient interventions and/or help in creating
better disease management and wellness programs. In this regards, the following
study has been done to better understand the T2DM disease progression;
specifically onset and “remission” of the T2DM, using administrative claims data,
with three objectives as mentioned below.
T2DM – Onset
The first objective of this study is to understand the factors that predict the
onset of T2DM. Previous studies have identified several risk factors associated
with onset of T2DM. Some of these risk factors were family history of T2DM, age,
obesity, and physical inactivity, prior history of gestational diabetes, impaired
glucose tolerance, dipocytokines, inflammatory factors and hepatocyte factors,
race/ethnicity, alcohol consumption, smoking/chewing tobacco, diet (6-11), high
blood pressure (12), appendicectomy (13), and hypothyroidism (14). However,
there is still additional opportunity to further understand these and other factors
that are associated with the onset of T2DM, especially in the Medicare 65 years
and older population. One example of this opportunity is to understand the
demographic, clinical and pharmacological factors that are associated with onset
of T2DM.
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It is important to understand the factors that are associated with the onset of
T2DM because T2DM has a long asymptomatic phase (15). People can
sometimes be unaware that they have diabetes for 4 to 7 years before an actual
diagnosis (16, 17). Hence understanding these factors will help design better
T2DM prevention program and help in early intervention. Even in cases where
T2DM is identified later in its progression (due to late diagnosis), improved
glycemic control is still beneficial and improves quality of life (18).
T2DM – “Remission”
The second objective of this study is to evaluate rate of T2DM “remission” in
Medicare patients. The third objective of this study is to understand the factors
that are associated with “remission” of T2DM. Even though it’s rare, T2DM
“remission” does occur in population without bariatric surgery (19, 20). However,
there is very little available literature around the factors that are associated with
“remission” among individuals with T2DM, who received usual care in Medicare
65 years and older population.
It is important to understand the factors associated with T2DM “remission”
because T2DM is a progressive condition (21-23), i.e., if left unmanaged, as
T2DM progresses the body’s natural ability to regulate blood sugar decreases. In
many patients the metabolic abnormalities associated with increased blood sugar
(or hyperglycemia) leads to macrovascular (coronary artery disease, peripheral
arterial disease, and stroke) and microvascular (diabetic nephropathy,
neuropathy, and retinopathy) complications (2, 24, 25). Understanding the factors
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associated with “remission” will help design better T2DM management
programs.
In summary, the study presented herein is aimed to enhance our
understanding about T2DM disease progression, to in turn help identify ways to
design better interventions. In order to achieve this, the study focuses on the
following three aims and hypotheses.
Study Aims and Hypotheses
a) T2DM – Onset
Aim 1: What are the factors that predict T2DM onset?
H0: The sociodemographic and clinical profile of Medicare patients 65 years and
older, who have T2DM onset, are not statistically different from those who do not
have T2DM onset.
HA: The sociodemographic and clinical profile of Medicare patients 65 years and
older, who have T2DM onset, are statistically different from those who do not
have T2DM onset.
b) T2DM – Rate of “Remission”
Aim 2: What is the rate of T2DM “remission?”
H0: T2DM Medicare patients 65 years and older, who received usual care without
bariatric surgery, never achieve T2DM “remission.”
HA: “Remission” is possible in T2DM Medicare patients 65 years and older, who
received usual care without bariatric surgery.

4

c) T2DM – “Remission”
Aim 3: What are the factors that predict T2DM “remission?”
H0: The sociodemographic and clinical profile of Medicare patients 65 years and
older, who have T2DM “remission”, are not statistically different from those who
do not have T2DM “remission.”
HA: The sociodemographic and clinical profile of Medicare patients 65 years and
older, who have T2DM “remission”, are statistically different from those who do
not have T2DM “remission.”
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LITERATURE REVIEW

Factors Affecting the Health of an Individual
The United States (U.S.) spent nearly $3.0 trillion, or $9,523 per person in
2014 on health care costs, which was about 17.5 percent of the gross domestic
product (GDP) (26). The U.S. is projected to spend nearly $5.4 trillion, or 19.6
percent of GDP by 2024 on health care costs (27). At its current growth rate,
spending on health care can adversely affect funding to other areas such as
education, research and development, infrastructure, defense, and other public
goods and services (28, 29). The U.S. spends more money per member per year
on health care than any other country. Despite such costs, the U.S. ranks lower
on key health measures such as life expectancy at birth, amenable mortality,
etc., than other comparable nations (30, 31), which suggests that spending on
health care does not always reflect quality of health (32).
Prior studies have demonstrated that health care accounts for only 1020% of variability in health outcomes, while 80-90% of the variability in health
outcomes results from other determinants such as individual behavior (40%),
socioeconomic factors (20%) and genetics (30%) (33-35).
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These factors (or determinants of health) that either directly or indirectly affect
the health and well-being of an individual can be broadly categorized into the
following groups:


Health care: Includes sub-components such as access to health care, quality
of health service and cost of health care services;



Health behavior: Health behavioral factors are often modifiable and include
factors such as level of engagement in one’s own health, motivation to walk,
diet, physical activity, tobacco consumption, alcohol consumption,
participation in a wellness program, participation in a disease management
program and managing stress;



Other factors: Includes factors that can or cannot be modified by an
individual: such as social (factors such as relationships with family and
friends); economic (factors such as income, net worth); political (factors such
as government policies, community); current health status of an individual
(factors such as disabilities, current clinical conditions); biological (factors
such as genetic); and, physical environmental (factors such as urban/rural,
pollution) determinants (36) (Figure 2.1).
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Figure 2.1: Factors effecting the health and wellness of an individual

Healthcare
(Access, cost and quality)
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(Social,
economic,
political,
environmental)

Health &
Wellness
eing

Health Behavior

Therefore health of an individual is affected by multiple factors, often
interacting with each other.
Health Determinants and Chronic Conditions
Chronic conditions like cancer, stroke, diabetes, heart disease, respiratory
diseases etc., are among the leading causes for death, morbidity and disability in
the U.S. (37). Chronic conditions account for 70 percent of deaths among
Americans (38) and 75 percent of the cost of health care (39). Most of these
chronic conditions are highly associated with factors such as: diet; physical
activity; alcohol and tobacco consumption; social; and, environmental (40-44).
Chronic diseases are costly yet often preventable. In order to alleviate the
burden of chronic conditions, public health and health care systems must design
interventions to address these risk factors. These interventions will help in early
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detection, slow or stop progression of the chronic condition and reduce
complications. This will in turn help in improving the quality of life and reduce the
cost burden on health care and public health systems (45).
The first step in designing an effective disease intervention is to
understand the factors that impact the onset of a chronic condition. This
understanding will not only help designing effective comprehensive disease
management and wellness programs but also help providers with a better
understanding about its prognosis and treatment which, will in turn aid in disease
counseling, and management.
Diabetes
Type 1 and Type 2 Diabetes
Diabetes is a chronic metabolic condition in which the body has a
decreased ability to secrete insulin, a defect in insulin action or both (46). The
two main etiopathogenetic categories of diabetes are type 1 and type 2 diabetes.
Type 1 diabetes is an auto-immune disease that is characterized by an absolute
lack of insulin secretion. Type 1 diabetes occurs in 5 to 10 percent of diabetes
cases (47).
The second and more prevalent category of diabetes is type 2 diabetes
mellitus (T2DM). T2DM is sometimes also referred as “non-insulin-dependent
diabetes” or “adult-onset diabetes.” T2DM accounts for 90 to 95 percent of
diabetes cases (48) and is primarily characterized by worsening of insulin
resistance and decline in beta cell (or β-cell) function. Beta cells produce and
secrete insulin – the hormone that regulates blood glucose levels. This glucose
9

imbalance can have a detrimental effect on how the body functions and can lead
to other comorbidities (more details in the sub section below). This literature
study focused on diagnosed T2DM. It excluded type 1 diabetes.
Cost and Importance
T2DM is the seventh leading underlying cause of death (49). Diagnosed
T2DM accounts for nearly 10 percent of the cost of health care dollar (50). In
2012, the total economic cost of T2DM was $245 billion dollars in the U.S. The
major component of this cost was hospitalization (43% of the total medical cost).
The medical expenses of people with diagnosed T2DM are 2.3 times that of a
non-diabetics (5). Worldwide, an estimated 336 million have T2DM and it is
projected that by 2030 nearly 552 million people will have T2DM (51).
T2DM is a Progressive Disease Condition
T2DM Onset
T2DM can have a long asymptomatic phase (15). People often are
unaware that they have T2DM for 4 to 7 years before an actual diagnosis (16, 17,
52). The onset of T2DM is generally preceded by a condition known as prediabetes (53). Pre-diabetes is a condition when the blood sugar is higher than
normal, but not high enough to be classified as T2DM (54). Without intervention,
pre-diabetes will most likely lead to the development of T2DM (55).
In this document the term “T2DM onset” refers to the onset of T2DM and
not the onset of pre-diabetes. The term “T2DM onset” is used when an individual
is diagnosed with T2DM for the first time during study period.

10

Risk factors – Onset
Previous studies have identified several risk factors associated with the
onset of T2DM such as physical inactivity, alcohol and tobacco consumption,
diet, family history of diabetes, aging, obesity, prior history of gestational
diabetes, impaired glucose tolerance, race/ethnicity, (6-11, 56-58), high blood
pressure (12), appendicectomy (13), hypothyroidism (14), depression and
anxiety (59). Pharmacological factors such as the use of statins also increases
the risk of T2DM by 10-12% (60), statins have a dose dependent class effect on
new-onset T2DM, i.e., the risk of developing T2DM increases with the increase in
statin dose (61). Previous studies have hypothesized that statins alter the
glucose homeostasis thereby causing T2DM onset (62). The speed of T2DM
progression depends on the age of the first diagnosis, the earlier the onset of
diabetes the more aggressive the progression or development of comorbidities
(56, 63).
Several of these risk factors were previously identified using clinical trials
and/or case control studies and might not be generalizable to community
settings. Also, some of these risk factors are not specific to late onset of T2DM,
especially in the 65 years and older population. Therefore, there is additional
opportunity to understand factors associated with T2DM progression. There is
not much literature available on the role of clinical conditions (such as
retinopathy, neuropathy, peripheral vascular disease and cardiovascular disease)
and demographics on T2DM onset and remission in T2DM Medicare patients 65
years or older (Figure 2.2).
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Figure 2.2: Illustration of the natural progression of T2DM

T2DM is a progressive disease. Glucose is a continuous variable, the use of thresholds such as pre-diabetic,
T2DM is somewhat arbitrary (64). The speed and direction of progression depends on several factors as
mentioned in the next sections.
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T2DM Onset and Progression – The Development of Complications
T2DM is a progressive condition. As T2DM progresses, the beta cells
gradually lose their ability to produce insulin, which then progresses to beta cell
failure and thereby requires insulin replacement (65). Long standing glucose
imbalances is a key risk factor for macrovascular complications such as
peripheral arterial disease (66), cerebrovascular (67), cardiovascular disease
(68-70) and microvascular complications such as neuropathy, retinopathy and
nephropathy (24, 64, 71-73). T2DM is also associated with other clinical
conditions such as dyslipidemia (74), hypertension (75), accelerated cognitive
aging (76), breast cancer, colon cancer, pancreatic cancer, other types of cancer
(77), mental health such as depression, anxiety, eating disorder (78), Parkinson’s
disease (79), disabilities (80) and mortality (81). These
complications/comorbidities (or simultaneous presence of other disease
conditions) are strongly associated with T2DM progression (64). Depending on
the number and stage of the complications, these pathologies can cause
significant disruption to the function of organs and body systems and thus effect
quality of life (82). These complications and the perceived ability to control the
disease, impacts the overall quality of life (83, 84). Hence the amelioration and
prevention of these complications is important and has been a goal of major
research in the recent years (85).
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Complications associated with T2DM
Hyperglycemia causes damage to vascular system. T2DM causes both
macrovascular (hypertension, hyperlipidemia, cardiovascular, cerebral vascular
disease, and peripheral vascular disease) and microvascular diseases
(retinopathy, nephropathy, and neuropathy) (86). This section discusses the key
vascular complications associated with T2DM.
Diabetic retinopathy: Retina is one of the most vascular regions in the human
body. The damage due to hyperglycemia can vary depending on the severity of
damage to the vascular system ranging from blurry vision to compete blindness.
Nearly 21% of patients diagnosed T2DM have retinopathy at the time of onset
(87).
Diabetic nephropathy: Diabetic nephropathy is also one of the important
vascular complications and a major cause of chronic kidney disease (88).
Diabetic neuropathy: Neuropathy causes loss of sensation in the feet, which in
turn causes callous formation. Neuropathy is associated with foot ulcers, nonhealing skin wounds and ulcers (89).
Cardiovascular diseases: Cardiovascular diseases associated with T2DM are
the primary cause of mortality and morbidity. This is the primary reason why
T2DM is the seventh largest cause of death in the United States (3).
Cerebrovascular: Cerebrovascular disease in T2DM is mainly because of
atherosclerosis. The brain vessels disease can cause cognitive impairment and
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is a risk factor for dementia, Alzheimer’s disease, transient ischemic attack (TIA)
and stroke (90).
Peripheral Vascular Disease (PVD): The key factors for PVD are vascular
smooth muscle cell dysfunction, inflammation, hypercoagulability and endothelial
dysfunction (91). PVD primarily involves aneurysm and claudication.
Other complications mentioned above such as cancers, cognitive aging, death,
are beyond the scope of this literature review.
Metabolic Syndrome and T2DM
Metabolic syndrome is characterized by a group of risk factors that raises
the risk of heart disease and other health problems such as stroke or diabetes.
These risk factors include large waistline, high triglyceride level, low HDL
cholesterol level, high blood pressure, high fasting blood sugar (92, 93). Patients
with metabolic syndrome are at a higher risk of developing T2DM by threefold
and the risk of developing cardiovascular diseases by two fold (94-96). This
study does not use metabolic syndrome as a predictor or classifier, due to the
lack of HbA1c data and glucose data.
Diabetes Complications Severity Index (DCSI Score)
The severity of the above mentioned T2DM complications varies from one
patient to another. Therefore the severity of the disease varies depending on the
stage of diabetes (pre-diabetes vs. T2DM) and/or the presence of T2DM related
complications. An individual with pre-diabetes and no complications is
considered having the least severity due to T2DM, while a T2DM patient with
15

multiple complications would be considered having the most severity due to
T2DM (more details below). Individuals who die due to T2DM related
complications theoretically have the most severe complications, but are excluded
in the study presented below.
The complications associated with T2DM usually develop simultaneously or
consecutively rather than independently. Hence a simple count of complications
will not provide sufficient measure of T2DM disease progression and severity.
Therefore an indicator (or score) was previously developed to quantify the
severity of diabetic complications (97, 98). This indicator is called the Diabetes
Complications Severity Index (DCSI) and models the severity of diabetes
complication at any given point of time in the patient’s life. DCSI can hence be
used to access patient’s risk of adverse outcomes (like hospitalization or death).
Administrative claims (medical, pharmacy and lab data) are used to calculate
DCSI. This score was subsequently validated (99) and adopted by other
researchers (100-104). This study uses DCSI scores to quantify T2DM diabetes
severity.
T2DM Onset Followed by “Remission”
T2DM disease progression is generally regarded as irreversible (105).
However with certain types of interventions such as bariatric surgery, metabolic
surgery, lifestyle efforts (e.g., weight loss and exercise), in certain individuals
T2DM “remission” is observed. This literature review excluded remission due to
bariatric/metabolic surgery because the focus of the study was to understand the
factors associated with remission in a non-surgery based setting.
16

Remission – Definition
The American Diabetes Association (ADA) has proposed the following definitions
for T2DM remission (106).
a) Partial remission: Partial remission is defined as sub-diabetic hyperglycemia
without active pharmacologic therapy or ongoing procedures for at least 1 year.
Sub-diabetic hyperglycemia is when HbA1c < 6.5% and/or fasting glucose 100–
125 mg/dL [5.6–6.9 mmol/l].
b) Complete remission: Complete remission is defined as “normal” measures of
glucose metabolism without active pharmacologic therapy or ongoing procedures
for at least 1 year. Normal measure of glucose metabolism is when HbA1c in the
normal range, < 5.7%, < 39 mmol/mol, fasting glucose < 100 mg/dl [5.6 mmol/l])
c) Prolonged remission: Complete remission for at least 5 years.
Since, T2DM is a chronic disease and individuals who go into remission are at a
high risk of relapse, the term cure is not used by ADA for even prolonged
remission because cure is generally the restoration of health, whereas remission
is the abatement of signs and symptoms of disease (106).
Risk factors – Remission
Current understanding about T2DM remission due to non-bariatric
intervention is limited. The recent post hoc randomized controlled study from the
Look AHEAD (Action for Health for Diabetes) and the 2014 Kaiser Permanente
study suggest that factors such as age, race, time since diagnosis, baseline
HbA1c level and taking diabetes medication at baseline are associated with
17

T2DM remission (19, 20, 107). There is also limited information on how T2DM
remission occurs in a usual care setting especially in the Medicare patients 65
years or older.
T2DM Management
The American Diabetes Association’s (ADA’s) “Standards of Medical Care
in Diabetes – 2016” provided details on several components of T2DM
management, care, general treatment goals, and tools to evaluate the quality of
care (108). Reviewing these factors for the study is important because an
individual who is managing their T2DM will favorably alter the disease
progression (109). Therefore this section of the literature review highlights some
of the key T2DM management and interventions.
Treatment of T2DM generally includes lifestyle interventions and/or
medical interventions (or non-lifestyle related diabetes management).
T2DM - Lifestyle Interventions
Lifestyle interventions of diabetes generally include education, nutritional
therapy, blood sugar monitoring and physical activity.
Education: The first and probably the most important component of diabetes
management is patient education, i.e., make the patient aware of the disease
condition (110). Such educational programs may include information about the
complexity of diabetes, its potential impact if left unmanaged, information on
healthy eating, methods to stay physically active, etc. Education is effective in
improving outcomes related to diabetes (111-116). However, there is no “one
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size fits all” educational program for diabetics. At a macro level, the role of
education is well established, for example, it is demonstrated that education
programs that help in modifying behavioral and psychosocial aspects have
improved health outcomes (117-119). However, when designing, testing and
implementing an education program at a micro level to a particular diabetic
individual or group, several other variables such as trust on the source of
education material, leadership, partnership, might also be important (120).
Nutrition: Nutrition is a key component of diabetes management. However, as
with education, there is no single nutritional strategy that works the best for all
diabetics (121). A nutritional management program is designed to motivate
individuals with T2DM to make healthy food choices.
Physical activities: Regular physical activities reduce the risk of diabetic
progression (122). American Diabetes Association recommends 90 minutes of
vigorous physical activity or 150 minutes of moderate physical activity per week.
As cardiorespiratory fitness and physical activity increases, the associated health
benefits also increase proportionally (123-125).
Previous participation in physical activities were difficult to quantify unless
under study conditions. However with the advent of technology, numerous
devices such as pedometers, smart watches etc. are now available that can
accurately and passively capture some of the physical activity data and
information.
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T2DM – Medical Intervention – Pharmacy
Medical intervention can be in the form of pharmaceuticals such as oral
anti-diabetic medications and/or injectable therapies such as insulin. Providers
use several different types of T2DM medication. These medications might be
used individually or in combination, depending on requirement and may include
monotherapy e.g., use of metformin, dual therapy e.g., metformin + 1 st line agent
like Alpha-glucosidase inhibitors, triple therapy e.g., metformin + 1st line agent
+2nd line agent like Colesevelam, or insulin, etc. (126, 127).
T2DM – Medical Intervention – Surgery
In certain obese individuals with T2DM, medical intervention may also
include medically assisted weight loss, using surgery. Weight loss is generally
considered first in T2DM disease management (128), especially in obese T2DM
patients. Obese T2DM patients with sustained weight loss have been shown to
improve glycemic control. In certain patients weight loss can be achieved by
intervention strategies such as diet, physical activity, behavioral therapy, lifestyle
intervention, pharmacological therapy, bariatric (“weight-loss”) surgery and other
metabolic surgeries such as gastric banding (or procedures that involve
resecting, bypassing or transposing sections of the stomach and small intestine).
Bariatric surgery commonly includes gastric bypass such as Roux-en-Y-gastric
bypass (RYGBP), sleeve gastrectomy such as Laparoscopic Sleeve
Gastrectomy, adjustable gastric band, and biliopancreatic diversion with
duodenal switch (BPD/DS) (129). Bariatric and metabolic surgeries are often
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considered as an effective weight loss treatments for certain individuals with
severe obesity especially amongst adults with BMI ≥ 35 kg/m2.
Bariatric surgery has been proved to be effective in treating T2DM patients
whose BMI is 35 kg/m2 or higher (130) with a success of achieving T2DM
remission between 24% and 95% (131, 132). Bariatric surgery is different from
lifestyle intervention because not every individual qualify for a bariatric surgery,
also the mechanism for remission after bariatric surgery is still unclear and might
be different from the mechanism of remission following lifestyle intervention
(132). Therefore individuals with bariatric surgery were excluded from the
analysis.
T2DM - Disease Management Programs
Wellness Programs
Wellness programs utilize education (133), behavior modification (134),
counseling (135), and incentives (136), etc., to help make better health and
wellness choices. Wellness programs are generally offered either through
workplace (called workplace wellness programs) or directly to individuals (e.g.,
self-employed, Medicare members, etc.) (137) (Figure 2.3).
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Figure 2.3: Channels through which wellness programs are offered
Workplace Wellness
Programs
(Offered through Employer)

Wellness Program
(Directly offered to
Individuals)

C) Employees of employer
X - Health insurance +
Wellness program
Employer
(X)
D) Employees of employer
X - Wellness program only

A) Individual/nonemployees
- Health Insurance +
Wellness program

Health
Insurance
Provider

B) Individual/nonemployees
- Wellness program only

E) Employees of Insurance
provider
- Health insurance +
Wellness program

F) Employees of Insurance
provider
- Wellness program only

SelfInsured
Employer
(Y)

G) Employees of Employer
Y - Health Insurance +
Wellness program

H) Employees of Employer Y
- Wellness program only

The current study focused only on “A) Individual/non-employees – Health
Insurance + Wellness program.”
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Lifestyle interventions are a major component of wellness programs that
are offered by health insurance companies to their members (or policy holders).
These wellness programs are generally offered as an add-on to the health
insurance coverage for members. A wellness program could have multiple
“lifestyle intervention” related components such as education, diet, promoting
physical activity, campaigns related to medication adherence, annual health
assessments, etc. (138). Each “lifestyle intervention” component could have subcomponents. For example, the component “promoting physical activity” might
include sub-components like promoting walking, gym and yoga, 5k events for
encouraging running. Some members might prefer walking and some might
prefer going to a gym, while some might prefer a combination of these activities.
Wellness programs are generally offered in multiple formats to provide a “variety
of choices” to the participants and to foster those with preferential participation.
This study presented herein does not differentiate the type of lifestyle intervention
and only considered any non-bariatric lifestyle intervention.
Disease Management Programs
Health insurance providers also have several disease management programs
which are separate from the wellness programs. These disease management
programs are designed specifically for each disease and often provided in
addition to wellness programs. For example, the diabetes disease management
program might provide clinical guidance to their members who are pre-diabetic or
diagnosed with T2DM.
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Gap in Literature
A well designed lifestyle intervention; either as a standalone program or as
part of a comprehensive wellness program or T2DM disease management
program, includes components such as diet, exercise, education/counseling,
smoking cessation, behavior modification (139). Some of these lifestyle
interventions are hypothesized to achieve key outcomes such as decreased
health care cost, improved quality of life, improved health outcomes, stop or
delay the onset of T2DM, and stop or delay progression of T2DM complications
(110, 140). It is also noted that a single intervention will not be able to address all
the above factors at the same time, and might need multiple lifestyle
interventions at various phases of T2DM disease progression.
Some well-designed lifestyle intervention programs aimed at individuals
with T2DM have shown positive health outcomes (125, 141-143). Some lifestyle
intervention programs work, while some do not (144). Within those that work,
their level of success varies greatly from one program to another. Success of
these lifestyle intervention programs depend largely on whose perspective the
program is being implemented and may include: stakeholder (provider, insurance
agency, self); the goals of the program (to make money vs. keep individuals
healthy); program design (components/services offered in the lifestyle
intervention program); implementation (level of activation of the program,
incentives, penalties); and most importantly how the program is evaluated
(quality of life, unhealthy days, absenteeism). An effective lifestyle intervention
program is highly customized and engages the intended audience at an
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“individual level.” In order to achieve high level of customization, it is imperative
to understand questions such as: “what works?”; “how to engage?” and, “what
needs to be improved?” The study presented here does not evaluate all these
questions but focusses only on understanding the factors that predict T2DM
onset and “remission.”
Lifestyle interventions applied as a community based strategy are not
effective and need to be tailored (145). The first step in designing a
comprehensive lifestyle intervention programs for T2DM is to understand T2DM
progression. T2DM progression has the following components; a) before onset of
T2DM (prevention), factors associated with onset of T2DM; b) after onset of
T2DM (treatment/management), factors associated with progression and factors
associated with “remission.”
T2DM Onset
As discussed above, there is still a gap in the literature about the
association of clinical conditions (such as retinopathy, neuropathy, peripheral
vascular disease and metabolic disease) and demographics with the onset of
T2DM in Medicare patients 65 years and older.
T2DM “Remission”
There are unanswered questions about the role of lifestyle interventions in
T2DM “remission.” For example, what are the demographic, clinical factors that
are associated with individuals who have T2DM “remission” without bariatric
surgery?
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Even though lifestyle intervention is considered more effective than medical
intervention for pre-diabetic patients and patients with impaired glucose tolerance
(146-148), the role of lifestyle interventions for T2DM “remission” is still unclear.
Though there is already some evidence for the possibility of T2DM “remission”
outside bariatric surgery, the rate of incidence is relatively low. Hence there is
value in understanding the demographic, pharmacological and clinical factors
that are associated with T2DM “remission” without bariatric surgery.
In summary, the purpose of the study is to evaluate the following two questions
1. Progression to Onset: What are the factors that predict T2DM onset?
2. Progression to “Remission”: What are the factors that predict T2DM
“remission?”
Importance of this Study
a) Monetary Impact: Potential saving of $3 to $4.6 billion in savings annually in
Kentucky (149).
b) Quality of life: More healthy and happy days due to reduced morbidity.
c) The need for efficient intervention:
Stakeholders such as health care systems, providers and payors do not have
unlimited resources to use blanket approaches for intervention. Organizations
are using data analytics to help design efficient lifestyle intervention
programs. Data mining can provide valuable and actionable insights. These
insights can be used to design, test analyze, learn and revise specific
hypothesis. This continuous “test and learn” process will help optimize the
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allocation of scarce resources to high potential wellness initiatives (Figure
2.4). This will in turn help target the right individual with the right intervention.
Figure 2.4: Test and learn cycle of a wellness program implementation
Design

Revise

Test

Learn

Analyze

Also, rather than targeting the entire population for specific wellness
component, predictive analytics (like predictive models, segmentation, clustering)
of data can be used to create targeted high impact intervention to specific
audiences, thereby increasing adoption and success of the intervention.
d) Compression of Comorbidity
Compression of comorbidity is to postpone the age of the first onset of
chronic infirmity so that the lifetime illness burden is compressed into a shorted
period toward the age of death (150). In order to achieve compression of
morbidity, it is important to understand the prognosis of the disease and the
factors that impact the progression.
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METHODS

Study Design

The study is a retrospective cohort analysis using administrative Medicare
Advantage Prescription Drug (MAPD) health plan data from a large Managed
Care Organization (MCO). This administrative data included enrollment, medical
claims and pharmacy claims data. This data were collected during the standard
course of care. It was not originally collected for the purpose of research or any
new study of human or animal subjects. Prior to the start of the study this study
protocol was reviewed and approved by the University of Louisville Institutional
Review Board. This study was also reviewed by the MCO’s review board.
De-identification:
The data was de-identified before analysis using industry standard deidentification process. The following are some of the example identifiers that
were removed from the data as part of the MCO’s de-identification process
a. Names.
b. All geographic subdivisions smaller than a state, including street address,
city, county, precinct, zip Code, and their equivalent geographical codes.
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c. All elements of dates (except year) for dates directly related to an individual,
including birth date, admission date, discharge date, date of death; and all
ages over 89 and all elements of dates (including year) indicative of such age.
d. Telephone numbers, facsimile numbers, electronic mail addresses, social
security numbers, medical record numbers, health plan beneficiary numbers,
account numbers, certificate/license numbers, vehicle identifiers and serial
numbers, including license plate numbers, device identifiers and serial
numbers, web universal resource locators (url), internet protocol (IP) address
numbers, biometric identifiers, including fingerprints and voiceprints, full-face
photographic images and any comparable images.
e. Any other unique identifying number, characteristic, or code such as social
media handles/profile names/ids, mac address, mobile device id number or
mobile unique device ID.
Study Cohort
The federal government offers original Medicare insurance, which includes
Medicare Part A (Hospital Insurance) and Medicare Part B (Medical Insurance).
Part C (or Medicare advantage) is offered through private insurance companies
and include the benefits of Part A, Part B and sometimes the optional Part D
(Prescription Coverage) along with several choices of programs and services.
Individuals can only be enrolled in Part C if they qualify for Medicare Part A and
Part B.
The private MCO offers Medicare Advantage Prescription Drug Plan
(MAPD) a Part C plan, which has the benefits of Medicare Part A, Part B and
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Part D, to individuals (Individual MAPD) and groups (Group MAPD). The source
population for this study are individuals who enrolled (members) in MCO’s
individual MAPD plan. The steps taken to create the aggregated dataset are
mentioned below.
Data Aggregation – Steps, Inclusions and Exclusions
The data aggregation was done in Hadoop (using Spark, Scala and Hive).
Hadoop is an open source software framework for distributed processing and
distributed storage of very large datasets (151). Processing was done in Hadoop
because of the volume of the data. Means and frequencies were calculated in
Hadoop. This data was then moved into SAS 9.2 (SAS Institute Inc., Cary NC) to
calculate rate for T2DM onset and “remission.”
Step1: Identify active enrollees: Identify active MAPD enrollees who were
active with the MCO in 2015. There were > 2.4 million individuals who met this
criteria.
Step2: Include only Medicare age-ins: The study included only those members
whose initial eligibility for Medicare enrollment was based on their age. An
individual can qualify to receive Medicare benefits if they are at least 65 years in
the year of their Medicare enrollment and meet certain additional enrollment
criteria. Therefore this study excludes those people who qualify for Medicare for
any other reasons such as disabilities or end stage renal disease (ESRD). There
were 1.7 Million individuals who met this criteria.
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Step 3: Exclusions: Excluded individuals who did not have continuous
Individual MAPD coverage with MCO from January 2008 to December 2015.
This ensured that the inclusion of MAPD individual who had both medical and
pharmacy coverage through the MCO continuously for eight years with the MCO.
Individuals with bariatric surgery, polycystic ovary syndrome, lipodystrophy,
nephropathy, type 1 diabetes, lived in Puerto Rico, steroid induced T2DM were
excluded from the study. These conditions were identified using a combination of
diagnostic codes, procedure codes, and therapeutic drug description. There were
121,862 individuals in the study cohort after this exclusion.
Step4: Identify T2DM: T2DM individuals were identified using administrative
medical and pharmacy claims using the following criteria; at least two diagnoses
of T2DM (International Classification of Diseases, Ninth Revision, Clinical
Modification [ICD-9-CM] and/or (International Classification of Diseases, Tenth
Revision, Clinical Modification [ICD-10-CM]; at least two pharmacy scripts related
to T2DM; at least 2 claims (medical or pharmacy) related to T2DM. A minimum of
two claims was used in the identification of T2DM because this would help
exclude patients who were miscoded and patients who were suspected to have
T2DM but were never formally diagnosed. T2DM status was identified for each
year from 2008 to 2015.
Using eight years of data, each individual was assigned into a group
based on their T2DM status over 8 years (Table 3.1). Each individual was
assigned 8 character sequence to represent their T2DM status for each year
from 2008 to 2015, where character at position 1 represents T2DM status of
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2008; position 2 represents T2DM status of 2009 and so on. So a sequence
00000000 represents an individual who had no diabetes in any year 2008 to
2015 and a sequence 00000011 represents an individual who was identified to
have no T2DM from 2008 to 2013 and had a T2DM onset in 2014 and continued
to have T2DM in 2015. These groups were then categorized into three cohorts:
a) onset cohort; b) “remission” cohort; and, d) other cohort as described below.
Table 3.1: Exclusions
T2DM
Always T2DM
No T2DM
“Remission”
Onset
Newly diagnosed
+ “remission”
Other
combinations

Sequence§§
11111111
00000000
11111110, 11111100,
11111000, 11110000
00000001, 00000011,
00000111, 00001111
00000010, 00000110,
00000100, 00001100

n
9,559
85,076

XXXXXXXX

20,083

4,314
2,330

121,862 100.0%

Total
§§0

500

%
7.8%
Onset cohort
69.8% “Remission” cohort
“Remission” cohort
0.4%
Onset cohort
3.5%
Excluded
1.9%
Excluded
16.5%

= no T2DM and 1 = presence of T2DM

a) T2DM onset cohort
In order to be included in the onset cohort, individuals were required to
have no T2DM in the year 2008, 2009, 2010 and 2011. This condition enabled to
establish a natural history of T2DM for at least four years. The occurrence of
onset was evaluated in 2012, 2013, 2014 and 2015. Also, once an individual was
diagnosed with T2DM, only those who continued to have T2DM in the
subsequent years till the end of the study were considered to have a T2DM onset
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(Table 3.2). Individuals who did not have T2DM any year from 2008 through
2015 were considered as part of the no onset group (Table 3.2).
Table 3.2: T2DM onset
T2DM Diagnosis
2008§

2009

2010

2011

2012

2013

2014

2015

PATTERN§§

NO
NO
NO
NO
NO
NO
NO
NO
NO
NO

NO
NO
NO
NO
NO
NO
NO
YES
NO
NO

NO
NO
NO
NO
NO
NO
YES
YES
NO
NO

NO
NO
NO
NO
NO
YES
YES
YES
NO
NO

NO
NO
NO
NO
YES
YES
YES
YES
NO
NO

NO
NO
NO
YES
YES
YES
YES
YES
NO
YES

NO
NO
YES
YES
YES
YES
YES
YES
YES
NO

NO
YES
YES
YES
YES
YES
YES
YES
NO
YES

00000000
00000001
00000011
00000111
00001111
00011111
00111111
01111111
00000010
00000101

§NO
§§0

Description
No Onset
( n = 85,076)
Onset
(n = 4,314)
Onset
(Excluded)
No continuous
Onset (Excluded)

= no type 2 diabetes diagnosis, and YES = type 2 diabetes diagnosis

= no T2DM and 1 = presence of T2DM
The onset cohort had a total of 89,390 individuals. The censored variable

was binary (0, 1). The value of 1 was assigned for individuals who had a T2DM
onset (n= 4,314) and a value of 0 was assigned for individuals who did not have
T2DM in the eight years of study (n = 85,076).
b) “Remission” cohort
The definition of “remission” in this study was different from that used by
American Diabetes Association (ADA), because of the lack of HbA1c data. An
individual was considered to be in “remission” if they had two or more T2DM
related claims in previous years and had no T2DM related claim in the given
year. Some individual’s experience T2DM relapse followed by a year or two
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years of “remission.” Such individuals were excluded from the study i.e., upon
“remission” T2DM individuals were required to continue to have no T2DM related
claims till the end of study period i.e., 2015. Also, to be included in the T2DM
“remission” study cohort, individuals were required to have T2DM in the year
2008, 2009, 2010 and 2011 and either continue to be diabetic (no “remission”
group) or go into “remission” (“remission” group). This condition enabled to
establish a natural history of T2DM for at least four years. T2DM relapse can
happen in some individuals after “remission”. Those individuals who had relapse
after first “remission” were excluded from the study, in order to focus on only
those individuals who had continuous “remission” (Table 3.3).
Table 3.3: T2DM “Remission”
T2DM DIAGNOSIS
2008§
YES

2009
YES

2010
YES

2011
YES

2012
YES

2013
YES

2014
YES

2015
YES

PATTERN§§
11111111

YES
YES
YES
YES
YES
YES
YES
YES
YES

YES
YES
YES
YES
YES
YES
NO
YES
YES

YES
YES
YES
YES
YES
NO
NO
YES
YES

YES
YES
YES
YES
NO
NO
NO
YES
YES

YES
YES
YES
NO
NO
NO
NO
NO
NO

YES
YES
NO
NO
NO
NO
NO
NO
YES

YES
NO
NO
NO
NO
NO
NO
YES
NO

NO
NO
NO
NO
NO
NO
NO
YES
YES

11111110
11111100
11111000
11110000
11100000
11000000
10000000
11110011
11110101

§NO
§§0

Description
No “Remission”
( n = 9,559)
“Remission”
(n = 500)
“Remission”
(Excluded)
“Remission” + Relapse
(Excluded)

= no type 2 diabetes diagnosis, and YES = type 2 diabetes diagnosis

= no T2DM and 1 = presence of T2DM

The “remission” cohort had a total of 10,059 individuals. The censored
variable was binary (0, 1). The value of 1 was assigned for individuals who had a
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T2DM “remission” (n= 500)) and a value of 0 was assigned for individuals who
had T2DM every year from 2008 to 2015 (n = 9,559).
c) Other Cohort:
Among the 121,862 individuals in the study frame there were 18.4%
(16.5% + 1.9%) individuals who had T2DM combinations that did not meet our
definition of onset or “remission” as mentioned above. The individuals were
excluded from the analysis in order to account for only those individuals who
continued to have the event (either onset or “remission”) after its first occurrence
and excluded relapses. This study could have included these 18.4% individuals
in the analysis, but the behavior of individual who had a relapse is likely different
from those who did not have a relapse, a choice was made to exclude them from
this study.
Step5: Independent variables: After accounting for the inclusions and
exclusions, the remaining members were included in the analytical dataset.
These members are then tagged with additional data components. Primary topics
and data components are mentioned below:
a) Clinical tags: Clinical tags were binary indicators (member had clinical
condition Y/N) for each year from 2008 to 2015. These clinical conditions are
the key macrovascular and microvascular disease conditions that are
commonly associated with T2DM. Administrative medical claims were used
for identification of these clinical tags as described before (98). These clinical
conditions include; retinopathy (diabetic ophthalmologic disease, background
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retinopathy, other retinopathy, retinal edema, cystoid macular
edema/degeneration (CSME), other retinal disorders, proliferative retinopathy,
retinal detachment, blindness, vitreous hemorrhage); nephropathy (diabetic
nephropathy, acute glomerulonephritis, nephrotic syndrome, hypertension,
nephrosis, chronic glomerulonephritis, nephritis/nephropathy, chronic renal
failure, renal failure not otherwise specified, renal insufficiency); neuropathy
(diabetic neuropathy, amyotrophy, cranial nerve palsy, mononeuropathy,
Charcot’s arthropathy, polyneuropathy, neurogenic bladder, autonomic
neuropathy, gastroparesis/diarrhea, orthostatic hypotension) cerebrovascular
(transient ischemic attack, stroke); cardiovascular (atherosclerosis, other
ischemic heart disease, angina pectoris, other chronic IHD, myocardial
infarction, ventricular fibrillation arrest, atrial fibrillation arrest, other
atherosclerotic cardiovascular disease, old myocardial infarction, heart failure,
atherosclerosis severe, aortic aneurysm/dissection); peripheral vascular
disease PVD (diabetic PVD, other aneurysm in lower extremities, PVD, foot
wound complication, claudication intermittent, embolism/thrombosis (lower
extremity), gangrene, gas gangrene, ulcer of lower limbs); metabolic
(ketoacidosis , hyperosmolar, other coma). Apart from these clinical tags,
hypertension, hyperlipidemia were also included in the analysis.
The selection of these tags in the onset and “remission” cohort depended
on the definition of the clinical tags. For example, clinical tags such as
diabetic ophthalmologic disease (ICD 09 250.5x), Diabetic nephropathy (ICD9 250.4) were excluded in the onset cohort because these were included in
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the definition of T2DM. Please see chapter 4 and chapter 5 for specific list of
clinical conditions that were included in onset and “remission” study.
b) Pharmacy: Oral diabetes drug, insulin, statin were identified using
administrative pharmacy claims. The indicators were binary fields (Y/N).
c) Demographic data: Age, gender, state, race were obtained from enrollment
data.
d) DCSI score: The DCSI score was calculated using methodology as
described previously (98).
Step 6: Data Transformation
The final data was transformed to create an analytical dataset in a
“counting process” input style as previously described (152, 153), where each
observation represented a Medicare patient’s disease condition in a given year
(Table 3.4).
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Table 3.4: Sample dataset – counting process input style

ID
101
101
101
101
101
101
101
101

Year
2008
2009
2010
2011
2012
2013
2014
2015

Start
0
1
2
3
4
5
6
7

Stop
1
2
3
4
5
6
7
8

T2DM
1
1
1
1
0
0
0
0

Retinopathy
(Y/N) - 2008
(Y/N) - 2009
(Y/N) - 2010
(Y/N) - 2011
(Y/N) - 2012
(Y/N) - 2013
(Y/N) - 2014
(Y/N) - 2015

Neuropathy
(Y/N) – 2008
(Y/N) – 2009
(Y/N) – 2010
(Y/N) – 2011
(Y/N) – 2012
(Y/N) – 2013
(Y/N) – 2014
(Y/N) – 2015

xxx
(Y/N) - 2008
(Y/N) - 2009
(Y/N) - 2010
(Y/N) - 2011
(Y/N) - 2012
(Y/N) - 2013
(Y/N) - 2014
(Y/N) - 2015

102
102
102
102

2008
2009
2010
2011

0
1
2
0

1
2
3
1

1
1
1
1

(Y/N) - 2008
(Y/N) - 2009
(Y/N) - 2010
(Y/N) - 2011

(Y/N) – 2008
(Y/N) – 2009
(Y/N) – 2010
(Y/N) – 2011

(Y/N) - 2008
(Y/N) - 2009
(Y/N) - 2010
(Y/N) - 2011

.
.
.

.
.
.

.
.
.

.
.
.

.
.
.

.
.
.

.
.
.

.
.
.

103

2011

0

1

1

(Y/N) - 2011

(Y/N) – 2011

(Y/N) - 2011
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Table 3.5: Topics and example data elements included in the analytical data

Clinical
conditions

Description

Key data elements

Identified using medical and
pharmacy claims

Cardiovascular
Cerebrovascular
Peripheral Vascular Disease
Retinopathy
Metabolic
Neuropathy

Pharmacy

Member’s drug usage based on
their pharmacy claims

Enrollment Coverage with Managed Care
Organization (MCO)

Insulin
Statin
Coverage indicators

These variables were the key independent variables in the analysis (Table
3.5). In the “remission” cohort analysis DCSI score was included. DCSI score
was not included in the onset cohort analysis.
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Statistical Analysis
The data aggregation processes led to the creation of two separate
analytical cohorts; a) onset b) “remission.” These cohorts were analyzed
separately. The aggregated data was analyzed using the following statistical
methods;
a. Descriptive statistics: Calculate means, frequencies. Descriptive
statistics were used to generate member profile and rates.
b. Survival analysis: Cox proportional hazard models.
Cox proportional hazard models were specified to identify the significant
variables associated with T2DM onset and “remission.” Statistical significance
was assessed at α = 0.05. All variables were first included in the unadjusted
model. The variables which are significant (p<0.05) were used in an adjusted
model.

Presentation of Statistical Results
All results were reported in aggregated formats only. At no point were the
individual or member level information/results reported. Any cells which
contained less than 10 individuals were represented as “< 10.” No information is
reported at a zip code level or by using specific service dates. This was a
requirement from MCO, and helped in providing an additional layer of deidentification.
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Statistical Tools
Hadoop (Scala, Spark 1.6) and SAS 9.2 were used for data processing
and statistical analysis.
Summary of methods
This study used observational, descriptive, retrospective study using de-identified
secondary administrative data. The data was analyzed using SAS and Hadoop
and the results were presented in an aggregated format.

41

TYPE 2 DIABETES MELLITUS (T2DM) ONSET IN MEDICARE PATIENTS 65
YEARS AND OLDER
Short running title: T2DM Onset
Type 2 Diabetes Mellitus (T2DM) is a chronic condition wherein the beta cells
in the body do not produce enough insulin or the body does not use insulin well
enough (also called insulin resistance), or there is complete absence of insulin
production. T2DM is associated with deleterious macro- and microvascular
outcomes (1) and is the seventh leading cause of death in the U.S. affecting 29.1
million people (4). The total estimated national cost of diabetes in the U.S. in
2012 was more than $245 billion, up from $174 billion in 2007 (5).
T2DM can have a long asymptomatic phase i.e., an individual can sometimes
be unaware that they have T2DM for 4 to 7 years before an actual diagnosis
(15). The onset (or first occurrence of T2DM) is generally preceded by prediabetes, a condition where an individual’s blood sugar is higher than normal, but
not high enough to be classified as T2DM (54). Without intervention, pre-diabetes
will progress to T2DM onset (55). When left unmanaged, T2DM continues to
progress from onset to development of comorbidities and eventually lead to
death. T2DM is a progressive disease. Since glucose is a continuous variable,
the use of thresholds such as pre-diabetic or T2DM is somewhat arbitrary (64).
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Previous studies have identified several risk factors associated with T2DM
onset such as: family history of T2DM; age; obesity; physical inactivity; prior
history of gestational diabetes; impaired glucose tolerance; dipocytokines;
inflammatory factors and hepatocyte factors; race/ethnicity; alcohol consumption;
tobacco smoking; diet (6-8, 10, 11); high blood pressure (12); appendectomy
(13); and hypothyroidism (14). However, there is still additional opportunity to
further understand these and other factors that impact the onset of T2DM,
especially in the Medicare patients 65 years and older.
Understanding the impact of these comorbidities within the Medicare
population is important because the Medicare population differs from the
population at large in age, life expectancy, frequency of preexisting comorbid
conditions and comorbidities due to progression of T2DM. These differences in
turn affect the type of therapeutic and non-therapeutic interventions that are
appropriate for this population (154). Understanding these factors will help design
better T2DM prevention programs and thereby alleviate disease burden of T2DM
and its comorbidities via proactive early intervention. This information will also be
useful in cases where T2DM is identified later in its progression (due to late
diagnosis) because improved glycemic control is still beneficial and improves
quality of life (18).
Research Design and Methods
Study Design
This retrospective study used de-identified administrative healthcare
claims and enrollment data from a Medicare Advantage Prescription Drug
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(MAPD) health plan offered by a large multistate healthcare company (a
managed care organization, MCO). The data was collected during standard
course of care. It was not originally collected for the purpose of this study, or any
new study on human and animal subjects. Prior to the beginning of the study, this
study protocol was reviewed and approved by the Institutional Review Board at
University of Louisville. The study was also reviewed by the MCO’s privacy and
ethics committee.
Study Cohort
Individuals may qualify for MAPD if they were at least 65 years of age in
the year of their Medicare enrollment and met certain additional eligibility criteria.
A smaller portion of individuals also qualified for MAPD for reasons such as
disability or end stage renal disease (ESRD). Individuals whose initial eligibility
criteria for enrollment into MAPD were due to disability or ESRD were excluded
from this study.
The large multistate healthcare company insured > 2.4 million individuals
who had continuous MAPD coverage from January to December of 2015. Of
these > 2.4 million individuals, there were more than 1.7 million individuals who
had “age ≥ 65” as the original reason for Medicare entitlement. The rest qualified
under Medicare disability or ESRD eligibility provisions and were excluded from
this study. Of these 1.7 million individuals, there were 265,554 members who had
continuous MAPD coverage with the MCO from January 2008 to December
2015. Starting with the sampling frame of these 265,554 individuals, this study
excluded the following during 2008 and 2015: a) individuals who had bariatric
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surgery (including gastric bypass, laproscopic gastroenterostomy) (n = 619); b)
individuals with polycystic ovary syndrome (n = 131) and lipodystrophy (n = 718)
were excluded because these individuals may have medications which have
competing indications with T2DM; c) individuals with any diagnostic codes
related to nephropathy were excluded because a previous study published by
Kaiser Permanente indicated that worsening renal function could lead to
improved glycemic control (20). In the present study, chronic kidney disease
(CKD) was excluded (n = 109,243) in order to identify a population without
irreversible end organ damage. In the current study we excluded pre-existing
nephropathy (41.3%) of the study sample. Previous research suggested the rate
of CKD among individuals 65 years and older was 61% in a year. The CKD rate
in the current study was likely lower because individuals with “disability” and
“ESRD” as their initial reason for Medicare enrollment were excluded from the
sampling frame (155); d) individuals who had drug and/or steroid induced
diabetes were excluded because the pathway for T2DM onset in these
individuals may be different from normal pathways for T2DM onset (n = 3,436); e)
individuals with type 1 diabetes (determined by ICD codes) were excluded
because type 1 diabetes has a different etiology from T2DM (n = 25,535); f)
individuals who had T2DM related diagnostics codes only during inpatient
hospital stay and do not have T2DM diagnostic claims or T2DM related
pharmacy claims in a non-hospital setting were excluded to account for potential
surgery induced dysglycemia (n = 1,772); and, g) certain restricted groups as
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required by the MCO’s privacy and legal agreements were also excluded from
this study. The MCO’s IRB required this exclusion (n = 2,238).
Inclusions
To be included in T2DM onset cohort individuals were required to have no
T2DM related claims in years 2008, 2009, 2010 and 2011 and have one of the
following qualifiers: a) individuals who had no T2DM related claims in years
2012, 2013, 2014 and 2015; or b) individuals who had T2DM onset in any year
between 2012 and 2015. Upon onset, individuals were also required to have
T2DM related claims every year until the end of the study (Appendix 4.1).
After the above mentioned inclusion and exclusion criteria, the final T2DM
onset cohort included 89,390 Medicare patients. 4,314 individuals had T2DM
onset (T2DM onset group) and 85,076 individuals had no T2DM onset (no T2DM
onset group) during the study period (Appendix 4.1). The baseline year was
2011, since the entire study cohort had no T2DM in 2008, 2009, 2010 and 2011.
Case definitions
T2DM: T2DM individuals were identified using administrative medical and
pharmacy claims data using the following criteria: a) at least two diagnoses of
T2DM (International Classification of Diseases, Ninth Revision, Clinical
Modification [ICD-9-CM] and/or (International Classification of Diseases, Tenth
Revision, Clinical Modification [ICD-10-CM]; b) at least two pharmacy scripts
related to T2DM; and, c) at least 2 claims (medical or pharmacy) related to
T2DM. A minimum of two claims were used in the identification of T2DM as a
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means of excluding patients who were potentially miscoded and patients who
were suspected to have T2DM but were never formally diagnosed.
Covariates: T2DM co-morbidities were defined using administrative claims data
as described previously using both ICD-9 and ICD-10 diagnostic codes (98). The
following co-morbidities were included in the study: a) retinopathy: other
retinopathy, retinal edema, cystoid macular edema/degeneration (CSME), other
retinal disorders, retinal detachment and blindness; b) neuropathy: amyotrophy,
cranial nerve palsy, neurogenic bladder, gastroparesis/diarrhea and orthostatic
hypotension; c) cerebrovascular: transient ischemic attack, stroke; d)
cardiovascular diseases: atherosclerosis, other ischemic heart disease (IHD),
angina pectoris, other chronic IHD, myocardial infarction, ventricular fibrillation
and arrest, atrial fibrillation, arrest, other atherosclerotic cardiovascular disease,
old myocardial infarction, heart failure, atherosclerosis severe, and aortic
aneurysm/dissection; e) peripheral vascular disease (PVD): other aneurysm of
lower extremities, foot wound and complications, embolism/thrombosis in lower
extremities, ulcer of lower limbs; f) hypertension; and g) hyperlipidemia.
Demographic information (age, gender, and race) was based on
enrollment data. T2DM related pharmacy and statin use were determined using
administrative pharmacy data.
Statistical Analysis
Data aggregation and the implementation of inclusions and exclusions
was done in Hadoop (using Spark, Scala and Hive). Hadoop is an open source
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software framework for distributed processing and distributed storage of very
large datasets (151). The processing was done in Hadoop because of the
volume of the data which included ≥ 2.4 million individuals’ medical and
pharmacy claims data from 2008 to 2015. Means and frequencies to generate
member profiles was calculated using Hadoop. The analytical dataset was
created in a counting process input style (152, 153). This data was then moved
into SAS 9.2. (SAS Institute Inc., Cary NC) to calculate rate of T2DM onset. Cox
proportional hazard models were specified to identify the significant variables
associated with T2DM onset. SAS procedure PROC PHREG was used for Cox
proportional hazard models (152).
The unadjusted model was developed using demographic, pharmacy, and
clinical conditions. The level of significance for unadjusted models was p<0.05.
The model was developed using Cox proportional hazard. Variables that were
significant in the unadjusted model were then included in the adjusted model. In
the final analysis, the adjusted model included the demographic variables
(gender and race), pharmacy (statin use) and clinical conditions (hypertension,
hyperlipidemia, heart failure, ulcer of lower limbs, atherosclerosis, retinal edema,
gastroparesis, orthostatic hypotension, cerebrovascular, atherosclerosis, other
ischemic heart disease (IHD), other chronic IHD, myocardial infarction (MI),
ventricular fibrillation and arrest, other atherosclerotic cardiovascular disease
(ASCVD), old MI, atherosclerosis severe, embolism, blindness and low vision,
other retinopathy and angina pectoris ). The level of significance for all statistical
tests was p< 0.05.
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Results
There were 89,390 Medicare patients 65 years and older who did not have
T2DM in 2008, 2009, 2010 and 2011. Of these, 4,314 Medicare patients were
diagnosed with T2DM between 2012 and 2015, while the remaining 85,076
Medicare patients continued to have no T2DM diagnosis until the end of study,
i.e., 2015. The cumulative rate of diagnosed T2DM onset in the study cohort was
4.82% (4314/89,390) (Table 4.1). The rates of diagnosed T2DM were 0.82%,
0.88%, 1.04% and 2.09% in years 2012, 2013, 2014 and 2015, respectively.
In the baseline year (2011), the average age of Medicare patients in the
T2DM onset cohort (n = 4,314) was 72.1 years compared to the average age of
73.0 years for the no-onset cohort (n=85,076) (p<0.0001). The T2DM onset
cohort consisted of 60.3% females compared to 63.5% females in the no-onset
cohort (Table 4.1) (p<0.0001). Even though the difference in the gender (3.2%)
and age (1.9 years) are statistically significant, these groups are not very
significant from each other from a theoretical perspective (Table 4.1).
At baseline there were significantly more non-white (African American,
Hispanic) individuals (19.5%) in the T2DM onset cohort compared to the T2DM
no onset cohort (11.7%) (p<0.0001) (Table 4.1).
At baseline, the T2DM onset cohort had significantly higher prevalence of
disease conditions compared to no-onset cohort. Individuals in the T2DM onset
cohort had higher prevalence of clinical conditions such as hypertension (70.1%
vs. 59.1%), hyperlipidemia (69.4% vs. 59.5%), cardiovascular (atherosclerosis
(5.0% vs. 7.2%), other ischemic heart disease (0.8% vs 1.5%), angina pectoris
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(2.1% vs. 3.6%), other chronic ischemic heart disease (12.3% vs. 15.4%), other
atherosclerotic cardiovascular disease (0.9% vs. 1.3%), history of myocardial
infarction (3.2% vs. 4.6%), heart failure (3.1% vs. 4.8%)), (p< 0.05) (Table 4.2).
Even though the clinical conditions related to cardio vascular disease were
significant, they might not be a clinically significant difference (Table 4.2).
In bivariate and multivariate analysis, male gender, non-white (African
American, Hispanic), statin use, hypertension, hyperlipidemia, heart failure, ulcer
of lower limbs, atherosclerosis, other retinopathy, angina pectoris, blindness and
low vision, absence of other ischemic heart disease (IHD) was associated with
T2DM onset in Medicare patients (p<0.05) (Figure 4.1, Figure 4.2 and Appendix
4.2).
Conclusions
The four year rate of T2DM onset was 48.2 per 1000 population. The
average rate of T2DM onset was 12.05 per 1000 per year. This rate was
consistent with the unadjusted incidence of T2DM of 11.5 per 1000 in the U.S. 65
years or older population (4).
Previously published research has documented some of the risk factors
for T2DM on: family history of T2DM, age, obesity, and physical inactivity, prior
history of gestational diabetes race, alcohol consumption, tobacco smoking, diet
(6-8, 10, 11). Some of the known risk factors that characterize metabolic
syndrome, a precursor for T2DM: impaired glucose tolerance; dipocytokines;
inflammatory factors and hepatocyte factors; and hypertension (12, 156).
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Gender and Race: The study presented here found that males, non-white
(African American, Hispanic) are significantly associated with T2DM onset in the
Medicare patients. Male gender was more likely to be associated with T2DM
onset compared to female gender (p<0.0001). Previous studies found globally
that males are more likely to develop T2DM than females (157, 158). This trend
has changed over the last 50 years. Females were more likely to have diagnosed
T2DM, but in recent years, the increasing sedentary lifestyles and diets of males
appears to be associated with increased prevalence of T2DM (159, 160).
Consistent with prior studies, the current investigation found that African
Americans and Hispanics were more likely to have an onset of T2DM than
Caucasians in the Medicare population (161). These findings further emphasize
the need for culturally sensitive interventions to help ameliorate racial disparities
of T2DM onset especially in the elderly, sedentary population.
Statins: This study also evaluated the role of statin use on T2DM onset. The
HMG-CoA inhibitors (statins), are one of the most commonly prescribed drugs
worldwide to reduce cholesterol, and prevent or manage coronary heart disease
(162). In a meta-analysis of 13 randomized trials, the use of statins was
associated with a 9% increase in the risk of T2DM onset, with the risk being the
highest in the older population. However, considering its effect on reducing
coronary events, previous studies have recommended no change in clinical
decision making for medium to high risk of cardiovascular diseases (163). Similar
to prior studies, the present investigation found that statin use was associated
with the onset of T2DM in Medicare patients (p<0.0001) and recommend
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surveillance of dysglycaemia among non-T2DM Medicare patients who are
receiving statin treatment.
Hypertension: High blood pressure affects approximately a billion people
worldwide and is a common yet modifiable risk factor for T2DM onset. Individuals
who have hypertension are 2.5 times more likely to develop T2DM (164, 165). In
the present study, hypertension is associated with T2DM onset (p<0.05).
Retinopathy: Prior investigations suggest that nearly 21% of individuals who are
diagnosed with T2DM also have some level of retinopathy at the time of
diagnosis (166). In individuals who do not have T2DM related retinopathy, the
symptoms are generally a manifestation of either retinal micro aneurysms or blot
hemorrhages. Advanced age and hypertension are associated with the
development of non-diabetic retinopathy but hypertension and T2DM are risk
factors for retinopathy in individuals who are < 65 years of age years (167).
The present study found that retinopathy (other retinopathy, blindness or
low vision) was associated with T2DM onset in Medicare patients (p<0.05). One
possible explanation is that when an optometrist or other provider evaluates a
Medicare individual for non-diabetic retinopathy, they might recommend T2DM
screening. This interaction with their provider and subsequent evaluation of blood
glucose can lead to diagnosis of T2DM.
Hyperlipidemia: Hyperlipidemia is key component of metabolic syndrome.
Metabolic syndrome refers to the co-occurrence of several known cardiovascular
risk factors such as atherogenic dyslipidemia (elevated triglycerides and low
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high-density lipoprotein [HDL]), high blood pressures, elevated glucose levels,
and abdominal obesity with pro-thrombotic and pro-inflammatory states (168).
These conditions have a common pathway and are interrelated. Individuals with
metabolic syndrome are at a significantly higher risk of developing T2DM (169).
In the study presented here, hyperlipidemia was associated with T2DM onset in
the Medicare patients (p<0.05). Hyperlipidemia and hypertension are significant
predictors of T2DM onset, and may be a proxy for metabolic syndrome as a
predictor for T2DM onset (170).
Peripheral vascular disease (PVD): PVD is characterized by vascular smooth
muscle cell dysfunction, endothelial dysfunction, inflammation and
hypercoagulability. PVD is a frequent comorbidity in T2DM. Vascular ulcers such
as ulcers of lower limbs are a common cause for older patients to visit a provider
(171). In the study presented here non-diabetic ulcer of lower limbs was
associated with T2DM onset in Medicare patients (p<0.05).
Cardiovascular disease (CVD): As previously mentioned above, metabolic
syndrome is characterized by clustering of risk factors such as prothrombotic,
hypertension and dyslipidemia. Metabolic syndrome independently contributes to
CVD and T2DM (172). This study evaluated several cardiovascular conditions
associated with T2DM: angina pectoris, atherosclerosis, heart failure, other
chronic IHD. Clinical and lab data related to metabolic syndrome was not
available, to further evaluate if the observed associations are due to the
underlying metabolic syndrome. Despite this limitation, these finding can still
provide valuable information to providers about the prognosis of the T2DM.
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Some of the cardiovascular conditions that were significantly associated with
T2DM were: a) angina pectoris: angina pectoris (angina) is characterized by
chest pain or discomfort, often associated with myocardial ischemia, arterial
insufficiency or hypoxia. Angina is generally a symptom for an underlying cause
such as coronary artery disease (173). Angina pectoris is associated with T2DM
onset in the present study (p<0.05). Associations found with angina and T2DM
onset must be re-evaluated by looking at the underlying causes; b) other chronic
IHD: this diagnostic code is associated with loss of elasticity and thickening of the
coronary arteries, leading to progressive arterial insufficiency. This study found
that in bivariate analysis other chronic IHD was associated with T2DM onset.
However when adjusted for other factors IHD had a protective effect on T2DM
onset. This finding suggests that individuals who have hypertension and
hyperlipidemia and also have IHD might have different behavior towards their
health and hence might be able to delay onset of T2DM (174).; c) heart failure
and atherosclerosis were associated with T2DM onset in Medicare patients.
In summary, male gender, non-white ethnicity (African American,
Hispanics), statin use, hypertension, hyperlipidemia, heart failure, ulcer of lower
limbs, atherosclerosis, other retinopathy, angina pectoris, blindness and low
vision, absence of other chronic ischemic heart disease (IHD) was associated
with T2DM onset in Medicare patients. African American and Hispanics (without
regard to gender), statins, hyperlipidemia, and hypertension are findings in
agreement with previously reported risk factors with development of T2DM. The
new associations with T2DM discovered in this investigation include: heart
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failure, ulcer of lower limbs, atherosclerosis, other retinopathy, angina pectoris,
blindness and low vision, and absence of other chronic ischemic heart disease
(IHD).

Note: The tables and figures are placed at the end of the article as per the
requirement of the journal.
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Tables and Figure Legends
Table 4.1: Baseline demographic and T2DM onset characteristics
Characteristic
Age, mean (SD), years
Female sex
Race/ethnicity
White
Black
Others

No Onset*
(n = 85,076)
73.0 (5.6)
63.5%

Onset **
(n = 4,314)
72.1 (5.1)
60.3%

75,051 (88.3)
6,316 (7.4)
3,640 (4.3)

3,465 (80.5)
542 (12.5)
300 (7.0)

Data are represented as n (%).
*Missing data in no onset cohort: race (n = 69).
**Missing data in onset cohort: race (n = 7).
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P value
<.0001
<.0001
<.0001

Table 4.2: Baseline comorbidities
Characteristic
Hypertension
Hyperlipidemia
Retinopathy
Other retinopathy
Retinal edema
CSME
Other retinal disorders
Retinal detachment
Blindness
Neuropathy
Neurogenic bladder
Gastroparesis/diarrhea
Orthostatic hypotension
Cerebrovascular
TIA
Stroke
Cardiovascular
Atherosclerosis
Other IHD
Angina pectoris
Other chronic IHD
Myocardial infarction
Ventricular fibrillation, arrest
Atrial fibrillation, arrest
Other ASCVD
Old myocardial infarction
Heart failure
Atherosclerosis, severe
Aortic aneurysm/dissection
Peripheral vascular disease
Other aneurysm, LE
Foot wound + complication
Embolism/thrombosis (LE)
Ulcer of lower limbs

No Onset
(n = 85,076)
50,336 (59.2)
50,636 (59.5)

Onset
(n = 4,314)
3,024 (70.1)
2,993 (69.4)

P value
<.0001
<.0001

795 (0.9)
351 (0.4)
430 (0.5)
294 (0.3)
647 (0.8)
535 (0.6)

42 (1.0)
15 (0.3)
26 (0.6)
10 (0.2)
37 (0.9)
32 (0.7)

0.7950
0.5150
0.3820
0.2100
0.4750
0.3620

154 (0.2)
174 (0.2)
1,226 (1.4)

<10
12 (0.3)
57 (1.3)

0.7770
0.3000
0.5190

1,486 (1.7)
5,104 (6.0)

78 (1.8)
288 (6.7)

0.7640
0.0690

4,216 (5.0)
675 (0.8)
1,773 (2.1)
10,445 (12.3)
588 (0.7)
5,508 (6.5)
78 (0.1)
761 (0.9)
2,761 (3.2)
2,673 (3.1)
38 (0.0)
1,307 (1.5)

311 (7.2)
66 (1.5)
155 (3.6)
664 (15.4)
37 (0.9)
308 (7.1)
<10
55 (1.3)
197 (4.6)
208 (4.8)
<10
52 (1.2)

<.0001
<.0001
<.0001
<.0001
0.2000
0.0840
0.3220
0.0100
<.0001
<.0001
0.9590
0.0830

35 (0.0)
26 (0.0)
75 (0.1)
493 (0.6)

<10
<10
<10
22 (0.5)

0.3770
0.7860
0.5520
0.5560

Data are expressed as n (%). Baseline year = 2011.
IHD, ischemic heart disease; LE, lower extremity; TIA, transient ischemic attack;
ASCVD, atherosclerotic cardiovascular disease
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Figure 4.1: Unadjusted Cox proportional hazard for T2DM onset

MI, Myocardial infarction; ASCVD, atherosclerotic cardiovascular disease; IHD,
ischemic heart disease; Race other, non-white and non-African American.

58

Figure 4.2: Adjusted Cox proportional hazard for T2DM onset

IHD, ischemic heart disease; Race other, non-white and non-African American.
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Appendix 4.1: T2DM Onset
T2DM Diagnosis
2009

2010

2011

2012

2013

2014

2015

PATTERN§§

NO

NO

NO

NO

NO

NO

NO

NO

00000000

Description
No onset
( n = 85,076)

NO
NO

NO
NO

NO
NO

NO
NO

NO
NO

NO
NO

NO
YES

YES
YES

00000001
00000011

Onset

NO

NO

NO

NO

NO

YES

YES

YES

00000111

(n = 4,314)

NO

NO

NO

NO

YES

YES

YES

YES

00001111

NO

NO

NO

YES

YES

YES

YES

YES

00011111

Onset

NO

NO

YES

YES

YES

YES

YES

YES

00111111

(excluded)

NO

YES

YES

YES

YES

YES

YES

YES

01111111

NO

NO

NO

NO

NO

NO

YES

NO

00000010

60

2008§

NO
NO
NO
NO
NO
YES
NO
YES
00000101
§NO = no type 2 diabetes diagnosis, and YES = type 2 diabetes diagnosis
§§0

= no T2DM and 1 = presence of T2DM

No continuous onset
(excluded)

Appendix 4.2: Unadjusted and adjusted Cox proportional hazard for T2DM onset
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Characteristic
Sex
Men
Women
Race
White
African American
Other
Statins
No statins
Statins
Clinical Conditions
No hypertension
Hypertension
No hyperlipidemia
Hyperlipidemia
Retinopathy
No other retinopathy
Other retinopathy
No retinal edema
Retinal edema
No blindness or low
vision

n (%)

Any onset (n = 4,314)
Hazard Ratio (95% CI)
Unadjusted
P Value

Fully adjusted

P value

1,711 (5.2)
2,603 (4.6)

1.0 (ref)
<0.0001
0.83 (0.79 - 0.86)

1.0 (ref)
0.79 (0.76 - 0.83)

<0.0001

3,465 (4.4)
542 (7.9)
300 (7.6)

1.0 (ref)
<0.0001
1.86 (1.75 - 1.98)
1.75 (1.61 - 1.89)

1.0 (ref)
1.76 (1.65 - 1.88)
1.66 (1.53 - 1.81)

<0.0001

2,228 (4.2)
2,086 (5.7)

1.0 (ref)
<0.0001
2.04 (1.96 - 2.13)

1.0 (ref)
1.28 (1.22 - 1.35)

<0.0001

1,290 (3.6)
3,024 (5.7)
1,321 (3.7)
2,993 (5.6)

1.0 (ref)
<0.0001
2.91 (2.75 - 3.08)
1.0 (ref)
<0.0001
2.85 (2.69 - 3.01)

1.0 (ref)
2.12 (1.99 - 2.25)
1.0 (ref)
1.99 (1.88 - 2.12)

<0.0001

4,272 (4.8)
42 (5.0)
4,299 (4.8)
15 (4.1)

1.0 (ref)
<0.0001
1.51 (1.29 - 1.77)
1.0 (ref)
0.0303
1.31 (1.03 - 1.67)

1.0 (ref)
1.27 (1.09 - 1.49)
1.0 (ref)
1.19 (0.93 - 1.53)

0.0024

1.0 (ref)

0.0194

4,282 (4.8)

1.0 (ref)

<0.0001

<0.0001

0.1604

Characteristic
Blindness or low vision
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Neuropathy
No gastroparesis
Gastroparesis
No orthostatic
hypotension
Orthostatic hypotension
No cerebrovascular
Cerebrovascular
Cardiovascular
No atherosclerosis
Atherosclerosis
No other IHD
Other IHD
No angina pectoris
Angina pectoris
No other chronic
IHD
Other chronic IHD
No myocardial
infarction
Myocardial
infarction
No ventricular
fibrillation, arrest

Any onset (n = 4,314)
Hazard Ratio (95% CI)
Unadjusted
P Value
1.45 (1.22 - 1.73)

Fully adjusted
1.23 (1.03 - 1.47)

P value

4,302 (4.8)
12 (6.5)

1.0 (ref)
1.56 (1.07 - 2.26)

0.0193

1.0 (ref)
1.42 (0.98 - 2.06)

0.0641

4,257 (4.8)
57 (4.4)
3,992 (4.8)
322 (5.2)

1.0 (ref)
0.0007
1.24 (1.09 - 1.39)
1.0 (ref)
<0.0001
1.33 (1.25 - 1.42)

1.0 (ref)
0.99 (0.87 - 1.12)
1.0 (ref)
0.99 (0.92 - 1.06)

0.8693

4,003 (4.7)
311 (6.9)
4,248 (4.8)
66 (8.9)
4,159 (4.8)
155 (8.0)

1.0 (ref)
1.71 (1.61 - 1.81)
1.0 (ref)
1.83 (1.54 - 2.17)
1.0 (ref)
1.83 (1.67 - 2.02)

1.0 (ref)
1.31 (1.23 - 1.39)
1.0 (ref)
1.16 (0.97 - 1.39)
1.0 (ref)
1.23 (1.11 - 1.37)

<.0001

3,650 (4.7)
664 (6.0)

1.0 (ref)
<0.0001
1.43 (1.35 - 1.50)

n (%)
32 (5.6)

4,277 (4.8)

1.0 (ref)

37 (5.9)

1.66 (1.42 - 1.95)

4,006 (4.8)

1.0 (ref)

<0.0001
<0.0001
<0.0001

<0.0001

0.7160

0.1124
<.0001

1.0 (ref)
0.85 (0.79 - 0.91)

<.0001

1.0 (ref)

0.2523

1.10 (0.93 - 1.30)
<0.0001

1.0 (ref)

0.3138
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Characteristic
Ventricular
fibrillation, arrest
No other ASCVD
Other ASCVD
No old myocardial
infarction
Old myocardial
infarction
No heart Failure
Heart Failure
No Atherosclerosis
severe
Atherosclerosis
severe
PVD
No embolism
Embolism
No ulcer of lower
limbs
Ulcer of lower
limbs

n (%)

Any onset (n = 4,314)
Hazard Ratio (95% CI)
Unadjusted
P Value

Fully adjusted

P value

0.7064

308 (5.3)
4,259 (4.8)
55 (6.7)

1.25 (1.17 - 1.33)
1.0 (ref)
1.46 (1.34 - 1.60)

<0.0001

0.97 (0.90 - 1.03)
1.0 (ref)
1.02 (0.92 - 1.13)

4,117 (4.8)

1.0 (ref)

<0.0001

1.0 (ref)

0.7608

1.02 (0.92 - 1.13)
1.0 (ref)
1.42 (1.32 - 1.54)

<.0001

1.0 (ref)

0.4515

197 (6.7)
4,106 (4.7)
208 (7.2)

1.55 (1.42 - 1.70)
1.0 (ref)
<0.0001
1.81 (1.69 - 1.95)

(4.8)

1.0 (ref)

<0.0293

< 10 (5.0)

1.76 (1.06 - 2.91)

(4.8)
<10 (6.3)

1.0 (ref)
2.06 (1.41 - 3.00)

0.0002

1.0 (ref)
1.25 (0.85 - 1.83)

0.2633

4,292 (4.8)

1.0 (ref)

<0.0001

1.0 (ref)

0.0012

22 (4.3)

1.57 (1.30 - 1.89)

0.81 (0.48 - 1.39)

1.38 (1.14 - 1.67)

Fully adjusted model includes all variables in this table. Data represented as n (%) for baseline year (2011)
*Missing data in No Onset cohort: race (n = 69). **Missing data in Onset cohort: race (n = 7).

TYPE 2 DIABETES MELLITUS (T2DM) “REMISSION” IN MEDICARE
PATIENTS 65 YEARS AND OLDER WITHOUT BARIATRIC SURGERY
SHORT RUNNING TITLE: T2DM “REMISSION”
Type 2 diabetes mellitus (T2DM) is generally considered as a chronic,
incurable, progressive and life-long disease condition. T2DM disease
management focuses primarily on glycemic control and management of the
macro- and microvascular complications that may be associated with
hyperglycemia (175, 176). However, a growing body of evidence indicates that
T2DM remission can be achieved in certain individuals (107).
The American Diabetes Association (ADA) has defined the term remission
as “…achieving glycaemia below the diabetic range in the absence of active
pharmacologic or surgical therapy.” ADA classifies remission into one of the
following three types: a) partial remission, defined as sub-diabetic hyperglycemia
without active pharmacologic therapy or ongoing procedures for at least 1 year.
Sub-diabetic hyperglycemia is characterized by HbA1c < 6.5% and/or fasting
glucose 100–125 mg/dL [5.6–6.9 mmol/l]; b) complete remission, defined as
“normal” measures of glucose metabolism without active pharmacologic therapy
or ongoing procedures for at least 1 year. Normal measure of glucose
metabolism is when HbA1c is in the normal range, < 5.7%, <39 mmol/mol, fasting
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glucose <100 mg/dL [5.6 mmol/l]); and c) prolonged remission, defined as
complete remission for at least 5 years (106).
Current evidence on T2DM remission suggests that there are at least two
key approaches for T2DM remission namely, metabolic/bariatric surgery and/or
intensive lifestyle management (175). Of these two approaches, bariatric
(“weight-loss”) surgery has been proved to be effective in treating T2DM patients
whose BMI is 35 kg/m2 or higher (130) with a success of achieving T2DM
remission between 24% and 95% (131, 132). Bariatric surgery is considered
relatively safe with 30 day mortality between 0.1% and 1.1%. However, the risk
of developing acute complications and long term complications is high (17%).
The rate of reoperation following bariatric surgery is around 7% and patients are
often required to have a close postoperative medical monitoring (177-180).
Current understanding of T2DM remission among non-bariatric patients
intervention is very limited. A recent post hoc randomized controlled study from
the Look AHEAD (Action for Health for Diabetes) and the 2014 Kaiser
Permanente study have shown metabolic/bariatric surgery is not the only
pathway to remission. Although rare, T2DM remission does occur in certain
populations without bariatric surgery (19, 20, 107). However, very little is known
about remission and factors associated with it.
Understanding factors predictive of remission within the Medicare patients 65
years and older is important because Medicare population differs from population
at large by their age, life expectancy, and frequency of comorbidities (154), and
have a significantly higher prevalence of T2DM compared to the population at
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large (181). Therefore, understanding these factors have substantial clinical
relevance to the design of interventions which lead to remission. In addition,
these data could be used to help design better T2DM management programs.
In order to identify remission as per the ADA definition, a researcher would
need both pharmacy and laboratory data (HbA1c). However, laboratory test data
are not always available to researchers, especially to those researchers who only
rely on administrative claims data for their analytical work (99). Therefore, a
modified definition for remission is offered in the present study. In this
investigation, the modified definition of remission is enclosed in quotation marks
(as “remission”).
In summary, this study was conducted to estimate the rate of type 2 diabetes
mellitus (T2DM) “remission” and to identify the factors that are associated with
T2DM “remission” in Medicare patients 65 years and older who did not undergo
bariatric surgery using administrative healthcare claims data in the absence of
HbA1c data.
Research Design and Methods
Study Design
This study was a retrospective cohort analysis using Medicare Advantage
Prescription Drug (MAPD) health plan data. This administrative data includes
member level enrollment, medical claims and pharmacy claims data. These data
were collected during the standard course of care. It was not originally collected
for the purpose of research or any new study of human or animal subjects. Prior
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to the start of the study this study protocol was reviewed and approved by the
University of Louisville Institutional Review Board. The study was also approved
by the MCO’s review board.
Study Cohort
The federal government offers original Medicare insurance, which includes
Medicare Part A (Hospital Insurance) and Medicare Part B (Medical Insurance).
Part C (or Medicare advantage) are offered through private insurance
companies. Part C includes the benefits of Part A, Part B and sometimes the
optional Part D (prescription drug coverage) along with several choices of
programs and services specific to each Managed Care Organization (MCO).
Individuals can only be enrolled in Part C if they qualify for Medicare part A and
part B. An individual may qualify for Medicare if they are at least 65 years old in
the year of their Medicare enrollment and meet certain additional eligibility
criteria. In addition, some individuals may qualify for Medicare for other reasons
such as disabilities or end stage renal disease (ESRD). Individuals whose initial
reason for Medicare enrollment was either disability or ESRD were excluded
from the present study.
The large multistate MCO offers Medicare Advantage Prescription Drug
Plan (MAPD) a Part C plan, which includes the benefits of Medicare Part A, Part
B and Part D, to individuals. The MCO insured more than 2.4 million individuals
who had continuous MAPD coverage from January 1, 2008 to December 31,
2015. Of these ≥ 2.4 million individual more than 1.7 million MAPD individuals
had “age ≥ 65” as the original reason for Medicare enrollment. The remainder
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qualified under Medicare disability or ESRD eligibility provisions. Of these > 1.7
million members there were 265,554 members who had continuous MAPD
coverage with the MCO from January 2008 to December 2015.
The initial sample after the above exclusions of 265,554 members,
additional exclusions were: a) individuals who had a prior bariatric surgery
(including gastric bypass, laparoscopic gastroenterostomy) (n = 619); b)
individuals with polycystic ovary syndrome (n = 131), and lipodystrophy (n =
718); c) individuals with any diagnostic codes related to nephropathy were
excluded because it indicates irreversible end organ damage. In the current
study, the nephropathy exclusion resulted in excluding 41.3% of the study
sample. Previous research suggested that the rate of chronic kidney disease
(CKD) in individuals who are 65 years and older was 61%. CKD rate in the
current study was likely lower because individuals with “disability” and “ESRD” as
their initial reason for Medicare enrollment were excluded from the sample (155);
d) individuals who had pharmacy claims related to drug and/or steroid induced
diabetes were excluded (n = 3,436); e) individuals with type 1 diabetes were
identified using ICD codes and excluded because type 1 diabetes has a different
etiology from T2DM (n = 25,535); f) individuals who had T2DM related
diagnostics codes only during inpatient hospital stay and did not have T2DM
diagnostic claims or T2DM related pharmacy claims in a non-hospital setting
were excluded to account for potential surgery induced dysglycemia (n = 1,772);
g) certain restricted groups as required by the MCO’s privacy and legal
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agreements were also excluded from this study. The MCO’s IRB required this
exclusion (n = 2,238).
The definition of “remission” in this study was different from that used by
ADA, because of the lack of HbA1c data. An individual was encoded as being in
“remission” if they met the following criteria: a) had two or more T2DM related
claims in previous years; b) had no T2DM related claims in the given year; c)
upon “remission” T2DM individuals were required to continue to have no T2DM
related claims until the end of study period, 2015. This requirement excluded
individuals who experienced T2DM relapse. This study’s focus was only on
individuals who experienced continued “remission” and not intermittent
“remission.”
Individuals were required to have T2DM in the year 2008, 2009, 2010 and
2011 and either continue to be diabetic (no “remission” group) or achieve
“remission” (the “remission” group) to be included in the T2DM “remission” study
cohort. T2DM relapse can happen in some individuals after “remission.”
Individuals who had relapse after first “remission” were excluded from the study.
The final population included a total of 10,059. The “remission” group included
500 individuals and 9,559 patients in the no “remission group. Since the entire
study cohort had T2DM in 2008, 2009, 2010 and 2011, the baseline year was
2011 (Appendix 5.1).
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Case definitions
T2DM: T2DM individuals were identified using administrative medical and
pharmacy claims with the following criteria: at least two diagnoses of T2DM
(International Classification of Diseases, Ninth Revision, Clinical Modification
[ICD-9-CM] and/or (International Classification of Diseases, Tenth Revision,
Clinical Modification [ICD-10-CM]; at least two pharmacy prescriptions related to
T2DM; at least 2 claims (medical or pharmacy) related to T2DM. A minimum of
two claims was used in the identification of T2DM to exclude patients who were
miscoded and patients who were suspected to have T2DM but were never
formally diagnosed.
DCSI: The Diabetes Complications Severity Index (DCSI) models the severity of
diabetes complication at a specific point in the patient’s life. DCSI is calculated as
previously described (98, 99). The final output is a patient’s score (or index
value) with a range from 0 to 13. An individual with DCSI score of 0 indicates the
patient has the least severe diabetes. This DCSI score can be used to group the
members into high, medium and low diabetic severity.
Retinopathy: This study used ICD-9 and ICD-10 diagnostic codes to identify
diabetic ophthalmologic disease, background retinopathy, other retinopathy,
retinal edema, cystoid macular edema/degeneration (CSME), other retinal
disorders, proliferative retinopathy, retinal detachment, blindness, vitreous
hemorrhage). An individual with any of the above clinical conditions was encoded
as having retinopathy.
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Neuropathy: This study used ICD-9 and ICD-10 diagnostic codes to identify
diabetic neuropathy, amyotrophy, cranial nerve palsy, mononeuropathy,
Charcot’s arthropathy, polyneuropathy, neurogenic bladder, autonomic
neuropathy, gastroparesis/diarrhea, orthostatic hypotension. An individual with
any of the above clinical conditions was encoded as having neuropathy.
Peripheral Vascular Disease (PVD): This study used ICD-9 and ICD-10
diagnostic codes to identify diabetic PVD, other aneurysm lower extremities,
PVD, foot wound and complication, claudication, intermittent,
embolism/thrombosis lower extremities, gangrene, gas gangrene, ulcer of lower
limbs. An individual with any of these clinical conditions was encoded as having
PVD.
Covariates
T2DM related clinical conditions were defined using administrative claims
data as described previously using both ICD-9 and ICD-10 codes, where
applicable (98). Demographic information (age, gender and race) was based on
enrollment data. T2DM related pharmacy and statins use was determined using
administrative pharmacy claims data.
Statistical Analysis
Enrollment, medical and pharmacy claims data from 2008 to 2015 of more
than 2.4 million members were included in the data aggregation. The data
aggregation was done in Hadoop (using Spark, Scala and Hive). Hadoop is an
open source software framework for distributed processing and distributed
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storage of very large datasets (151). Processing was done in Hadoop because of
the volume of the data included. The analytical dataset was created in a counting
process input style (152, 153) Means and frequencies to generate member
profile were calculated in Hadoop. This data was then moved into SAS 9.2. (SAS
Institute Inc., Cary NC) to calculate rate for T2DM “remission.” Cox proportional
hazard models were specified to identify the significant variables associated with
T2DM “remission.” SAS procedure PROC PHREG was used for Cox proportional
hazard models (152). The adjusted model included demographic variables
(gender, and race), statin use, clinical conditions (hypertension, hyperlipidemia,
retinopathy, neuropathy, other chronic ischemic heart disease, other
atherosclerotic cardiovascular disease and peripheral vascular disease) and
DCSI score. The level of significance for all statistical tests was p < 0.05.
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Results
There were 10,059 MAPD individuals who had T2DM in 2008, 2009, 2010
and 2011. In the study period there were 4.97% (95% CI, 3.05% - 8.00%)
Medicare patients 65 years and older (n=500) who met the definition of T2DM
“remission” in the study cohort. At 2011, the baseline year, the average age of
the “remission” group was 73.7 years, while that of the non- “remission” group
was 72.6 years. In the “remission” group 62.2% were female, compared to 57.2%
in the non-“remission” group. 63.6% of the “remission” group did not use any
diabetes-related medications prior to going into “remission (Table 5.1).
At baseline, the T2DM “remission” group had significantly lower disease
prevalence of hypertension, hyperlipidemia, retinopathy (overall, diabetic
ophthalmologic disease, background retinopathy, retinal edema, and blindness),
neuropathy (overall, diabetic neuropathy, polyneuropathy) and diabetic peripheral
vascular disease. However, the “remission” group had higher cardiovascular
disease (overall, myocardial infarction, aortic aneurysm and dissection) (p<0.05)
(Table 5.2).
In bivariate and multivariate analyses, T2DM “remission” was associated
with no statin use, low diabetes complications severity index score, no
hypertension, no hyperlipidemia, no neuropathy, no retinopathy, race
(Asian/Hispanic), other chronic ischemic heart disease (IHD) and female gender
(p<0.05).
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In bivariate analysis “remission” was associated with ulcer of lower limbs
and peripheral vascular disease (PVD). However, these associations were
attenuated in multivariate analyses and were not significant (p>0.05) (Figure 5.1,
Figure 5.2 and Appendix 5.2).
Conclusions
In Medicare patients 65 years and older, T2DM “remission” does occur
without bariatric surgery. 4.97% (95% CI, 3.05% - 8.00%) of Medicare patients
65 years and older met the definition of T2DM “remission” in the study cohort.
This was not significantly different from the 2.2% (1.34% - 3.54%) of the 2014
Kaiser Permanente report on ≥ 65 year old population (20). It is significantly
different from the Look AHEAD study which reported T2DM remission incidence
of 11.5% (95% CI, 10.1%-12.8%) during the first year and 7.3% (95% CI, 6.2%8.4%) at 4 years in the intensive lifestyle intervention group. The percent
“remission” in the present study did not differ from the 2.0% remission reported
for the diabetes support and education control condition (DSE) group (P < 0.001)
(19). The study presented here found that T2DM “remission” indeed occurs in
Medicare patients 65 years and older who did not undergo bariatric surgery.
These findings are consistent with previous findings and challenge the
widespread notion that T2DM is irreversible in non-bariatric settings.
Consistent with the 2014 Kaiser and the Look AHEAD studies, this study
also found that the absence of hyperlipidemia was associated with T2DM
“remission.” As suggested in previous findings, hyperlipidemia, obesity, and
impaired glucose tolerance may have common biological pathway commonly
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called metabolic syndrome. These findings provide additional evidence of the
role of managing impaired lipid metabolism to slow or reverse T2DM progression.
Further, this study evaluated multiple clinical conditions related to
macrovascular and microvascular comorbidities that are typically associated with
T2DM. After adjusting for covariates this study found a number of variables
associated with T2DM “remission” that were not previously reported: no statin
use; low diabetes complications severity index score; no hypertension; no
neuropathy; no retinopathy; race (non-white and non-African American);
presence of other chronic ischemic heart disease (IHD) and females (p<0.05).
Gender: Globally, males are more likely to have T2DM than females (157, 158).
This trend has changed over the last 50 years. Previously, females were more
likely to have diagnosed T2DM, but in recent years, the increasing sedentary
lifestyle of males is attributed to their increased prevalence of T2DM (159, 160).
In line with these studies the current study found that females were more likely to
have a T2DM “remission” compared to males.
Race: Consistent with previous studies the current study found that Hispanics
and other non-white race (excluding African American) were more like to have a
T2DM ”remission” in the Medicare 65 years and older population (p<0.05) (161).
This finding emphasizes the need for public health policies to develop culturally
sensitive interventions to help ameliorate racial disparities of T2DM disease
management especially in the elderly population.
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Hypertension: Previous studies indicated that hypertension and T2DM generally
occur together and share several common risk factors such as obesity,
inflammation, and insulin resistance. Hypertension and T2DM also share
common pathways such as those associated with sympathetic nervous system
(SNS) and renin-angiotensin-aldosterone system (RAAS) (164). The present
study found that even in Medicare patients 65 years and older population the
absence of hypertension is associated with T2DM “remission” (p<0.05).
Statins: This study evaluated the role of statins on T2DM “remission” and found
that the absence of statin use is associated with T2DM “remission” (p<0.05).
There is no previous literature on the role of statin in T2DM “remission.”
However, its role on T2DM onset is well established. Statin therapy is associated
with a 9% increased risk of T2DM (163). Prior investigation also established that
the level of statin potency is associated with T2DM onset (182).
DCSI score: The complications associated with T2DM usually develop
simultaneously or consecutively rather than independently. A simple indicator for
T2DM related complications may not have been a sufficient measure of T2DM
disease progression. Therefore, in the present study, we used an indicator (or
score), as previously described, to quantify the severity of diabetic complications
(97, 98). This indicator is called the Diabetes Complications Severity Index
(DCSI) and models the severity of diabetes complication at any given point of
time in the patient’s life. Using the DCSI score, we further analyzed the
association between severity of T2DM and T2DM “remission,” and found that
lower DCSI scores (i.e., individuals who have less severe diabetes) are
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associated with T2DM “remission.” This finding is important because DCSI can
thus help in stratifying individuals with T2DM into groups based on score
severity. This information can later be used for selecting individuals into disease
management programs.
Retinopathy: Retinopathy is one of the most common microvascular damage
sites associated with T2DM. Diabetic retinopathy is a major public health
problem, with approximately one third of T2DM patients developing some form of
retinopathy (183). The healthy function of retina depends on availability of high
amounts of oxygen, which in turn depends on intact blood-retinal barrier. The
dysglycaemia associated with T2DM causes damage to this barrier by damaging
both the inner retinal barrier and/or causing microvascular occlusions. The
severity of such retinopathy might range from background retinopathy to
complete blindness depending on the level of damage (184). Previous studies
have recommended individuals with T2DM to control their blood sugar, blood
pressure, and body fat to control the risk of development of advanced retinopathy
(183).
Evidence in the present study found that the absence of any T2DM
retinopathy was associated with T2DM “remission (p<0.05). Taken in
combination with previous recommendations, this study suggests that providers
must educate T2DM about the possibility of “remission” by lifestyle modifications
a self-incentive for enabling modified behavior, and that they still have a chance
to reverse the progression of T2DM.
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Neuropathy: Neuropathy and diabetes are generally associated together. More
than 50% of T2DM individuals have neuropathy and more than 50% of
individuals with neuropathy have T2DM (89). The study presented here found
that the absence of neuropathy was associated with T2DM “remission” in
Medicare patients 65 years and older.
Neuropathy can be associated with several causes, including metabolic
injury (hyperglycemia), compressive injury, ischemic injuries, inflammatory and/or
immune response, and other comprehensive etiologies (185). This study did not
evaluate the specific reason associated with neuropathy due to the lack of
access to physician notes. In spite of this limitation, this finding provides valuable
insight into designing public health interventions; for example, individuals with
T2DM and without neuropathy may be educated about this finding to incentivize
them to make behavior and lifestyle changes.
Other Chronic IHD: IHD is the loss of elasticity and thickening of the coronary
arteries, leading to progressive arterial insufficiency. Individuals with “other
chronic IHD” were more likely to go into T2DM “remission.” This association is
not completely understood. One explanation of this association is that there may
be a small proportion of individuals in the study sample where the provider takes
them off their diabetic medication due to a variety of reasons, such as, the
caregiver is less aggressive in motivating patients to achieve lower HbA1c levels.
Another explanation for this association is that individuals who have certain
clinical conditions, such as those related to cardiovascular diseases, might be on
constant alert to make healthier choices, especially due to the constant
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reminders that they might be receiving from their provider, insurance agency.
These factors, and others, may be the reason why these individuals have a
different outcome compared to those without this clinical condition.
There were several limitations to this study. First and most important, the
study does not include clinical and laboratory findings such as physician notes
and HbA1c lab results, which would have provided a more accurate measure of
T2DM “remission.” Therefore, a small proportion of individuals could have been
asked by their doctors to stop taking T2DM medication for a variety of unknown
reasons as noted. The probability of this occurring in the data is very low
because even in those cases the physician will probably capture the T2DM
related diagnostic code on the medical claims. Also, as with other similar
retrospective studies there is a potential for error in information coded in the
administrative data. As in other retrospective studies it is not possible to establish
causation with such an analytic approach. The level or potency of the T2DM
medications including statins was not evaluated in this analysis. DCSI is an
unweighted composite index, and does not independently test individual
outcomes associated with each complication associated with T2DM. Metabolic
syndrome is also excluded from the study due to lack of data such as BMI and
physician notes.
In conclusion, T2DM “remission” in Medicare patients 65 years and older
is observed in a community setting in a small proportion of individuals who did
not undergo bariatric surgery. In majority of the remaining patients T2DM may
still remain a major burden and impact quality of life. This study helps establish
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additional evidence to the role of lifestyle intervention in T2DM progression and
provides some insights into the possibility of using behavior and lifestyle
interventions as alternate pathways for diabetes treatment and management.
Lifestyle interventions such as increased physical activity, low
carbohydrate diet, cessation of tobacco smoking, and reducing alcohol intake are
already recommended by providers to T2DM patients as a means to control
glucose, blood pressure and cholesterol. These study results can further help
providers discuss disease prognosis with their T2DM patients and in designing
efficacious interventions to the right individuals at the right time. This will help
design better T2DM management programs. For example, if a Medicare patient
65 years and older individual is diagnosed with T2DM and has not yet developed
any chronic comorbidities such as neuropathy or retinopathy, but has modifiable
comorbidities such as hypertension and hyperlipidemia, then their provider can
use the insights provided in this study to advise their patients about their
possibility to control their T2DM progression by participating in lifestyle
intervention programs. DCSI score can be used as an index to further tailor these
management programs.
These findings also have significant public health implications ranging
from health policy, clinical guidance design, built environment and incentives to
enable the success of these lifestyle intervention programs. Lastly, this study
recommends further investigation into the lifestyle pathway for T2DM “remission”
to improve our understanding of this beneficial alternative. Thus, it may be
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possible to increase the percent of individuals who might benefit from T2DM
“remission.”

Note: The tables and figures are placed at the end of the article as per the
requirement of the journal.
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Tables and Figure Legends
Table 5.1: Baseline demographic and T2DM “remission” characteristics
Characteristic
Age, mean (SD), years
Female sex
Race/ethnicity
White
Black
Others

No “Remission”*
(n = 9,559)
72.6 (5.1)
57.2%

“Remission”†
(n = 500)
73.7 (5.5)
62.2%

7,679 (80.4)
1,378 (14.4)
497 (5.2)

397 (79.6)
68 (13.6)
34 (6.8)

Data are represented as n (%), unless otherwise mentioned
*Missing data in no “remission” cohort: Race (n = 5)
†Missing data in "remission" cohort: Race (n = 1)
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P value
<.0001
0.0273
0.3542

Table 5.2: Baseline comorbidities

Characteristic
Hypertension
Hyperlipidemia
Retinopathy
Diabetic ophthalmologic disease
Background retinopathy
Other retinopathy
Retinal edema
Cystoid macular
edema/degeneration
Other retinal disorders
Proliferative retinopathy
Retinal detachment
Blindness
Vitreous hemorrhage
Neuropathy
Diabetic neuropathy
Mononeuropathy
Charcot’s arthropathy
Polyneuropathy
Neurogenic bladder
Autonomic neuropathy
Gastroparesis/diarrhea
Orthostatic hypotension
Cerebrovascular
Transient ischemic attack (TIA)
Stroke
Cardiovascular
Atherosclerosis
Other ischemic heart disease
Angina pectoris
Other chronic ischemic heart
disease
Myocardial infarction
Ventricular fibrillation, arrest
Atrial fibrillation, arrest
Other atherosclerotic
cardiovascular disease
Old myocardial infarction
Heart failure
Atherosclerosis, severe
Aortic aneurysm/dissection
Peripheral vascular disease

No
“Remission"*
(n = 9,559)
8,285 (86.7)
8,125 (85.0)
1,187 (12.4)
830 (8.7)
392 (4.1)
138 (1.4)
67 (0.7)

“Remission”†
(n = 500)
411 (82.2)
402 (80.4)
32 (6.4)
17 (3.4)
<10
<10
<10

P value
0.0040
0.0050
<0.0001
<0.0001
0.0010
0.6550
0.0600

64 (0.7)
40 (0.4)
61 (0.6)
72 (0.8)
55 (0.6)
21 (0.2)
1,801 (18.8)
1,395 (14.6)
356 (3.7)
<10
820 (8.6)
15 (0.2)
78 (0.8)
44 (0.5)
145 (1.5)
841 (8.8)
168 (1.8)
759 (7.9)
2,925 (30.6)
572 (6.0)
112 (1.2)
309 (3.2)

<10
<10
<10
<10
<10
<10
68 (13.6)
46 (9.2)
19 (3.8)
<10
20 (4.0)
<10
<10
<10
10 (2.0)
42 (8.4)
11 (2.2)
38 (7.6)
174 (34.8)
36 (7.2)
<10
16 (3.2)

0.2010
0.9500
0.0730
0.1550
0.0220
0.4110
0.0030
0.0010
0.9310
0.1870
<0.0001
0.8140
0.3070
0.3950
0.3930
0.7590
0.4660
0.7840
0.0470
0.2660
0.3900
0.9680

1,846 (19.3)
81 (0.8)
732 (7.7)
11 (0.1)

94 (18.8)
10 (2.0)
43 (8.6)
<10

0.7770
0.0080
0.4410
0.5920

138 (1.4)
462 (4.8)
503 (5.3)
<10
121 (1.3)
1,074 (11.2)

10 (2.0)
25 (5.0)
34 (6.8)
<10
17 (3.4)
60 (12.0)

0.3140
0.8650
0.1360
0.6090
<0.0001
0.5980
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No
“Remission"*
(n = 9,559)
524 (5.5)
<10
807 (8.4)
<10
623 (6.5)

Characteristic
Diabetic PVD
Other aneurysm, lower extremity
Peripheral vascular disease
Foot wound + complication
Claudication, intermittent
Embolism/thrombosis (lower
extremity)
<10
Gangrene
<10
Gas gangrene
<10
Ulcer of lower limbs
98 (1.0)
Metabolic
46 (0.5)
Ketoacidosis
16 (0.2)
Hyperosmolar
22 (0.2)
Other coma
<10
Data are expressed as n (%). Baseline year = 2011

“Remission”†
(n = 500)
16 (3.2)
<10
51 (10.2)
<10
46 (9.2)

P value
0.0270
0.0090
0.1700
0.7460
0.0190

<10
<10
<10
<10
<10
<10
<10
<10

0.0440
0.6470
0.8190
0.3530
0.3230
0.8630
0.4480
0.3960

If the number of individuals in a cell were less than 10, the number is replaced
with “< 10”
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Figure 5.1: Unadjusted Cox proportional hazard for T2DM “remission”

ASCVD, atherosclerotic cardiovascular disease; DCSI, Diabetes
complications severity index; IHD, ischemic heart disease. Race: other,
non-white and non-African American; PVD, peripheral vascular disease.
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Figure 5.2: Adjusted Cox proportional hazard for T2DM “remission”

DCSI: Diabetes complications severity index; IHD, ischemic heart disease;
Race: other, non-white and non-African American.
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Appendix: Table 5.1: T2DM “remission” definitions
T2DM Diagnosis
2008§ 2009 2010 2011 2012
YES

YES

YES

YES

YES

2013

2014 2015 PATTERN§§

YES

YES

YES

11111111

Description
No “Remission”
( n = 9,559)
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§NO
§§0

YES

YES

YES

YES

YES

YES

YES

NO

11111110

YES

YES

YES

YES

YES

YES

NO

NO

11111100

“Remission”

YES

YES

YES

YES

YES

NO

NO

NO

11111000

(n = 500)

YES

YES

YES

YES

NO

NO

NO

NO

11110000

YES

YES

YES

NO

NO

NO

NO

NO

11100000

“Remission”

YES

YES

NO

NO

NO

NO

NO

NO

11000000

(Excluded)

YES

NO

NO

NO

NO

NO

NO

NO

10000000

YES

YES

YES

YES

NO

NO

YES

YES

11110011

YES

YES

YES

YES

NO

YES

NO

YES

11110101

= no type 2 diabetes diagnosis, and YES = type 2 diabetes diagnosis

= no T2DM and 1 = presence of T2DM

“Remission” +
Relapse
(Excluded)

Appendix: Table 5.2 - Unadjusted and adjusted Cox proportional hazard for “remission”
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Characteristic
Gender
Males
Females
Race
White
Black
Other
DCSI Score
Zero
1-2
3+
Statins
No statins
Statins
Clinical Conditions
No hypertension
Hypertension
No hyperlipidemia
Hyperlipidemia
Retinopathy
No retinopathy
Retinopathy
Neuropathy
No neuropathy

n (%)
189 (4.4)
311 (5.3)

Any “Remission” (n = 500)
Hazard Ratio (95% CI)
Unadjusted
P Value
Fully adjusted

P value

1.0 (ref)
1.26 (1.12 - 1.42)

<0.0001

1.0 (ref)
1.33 (1.18 - 1.50)

397 (4.92)
1.0 (ref)
68 (4.7) 0.93 (0.78 - 1.10)
34 (6.4) 1.51 (1.21 - 1.87)

0.3936
0.0002

1.0 (ref)
1.01 (0.85 – 1.20
1.49 (1.21 - 1.86)

1.0 (ref)
<0.0001
0.48 (0.42 - 0.55)
0.36 (0.29 - 0.44)

1.0 (ref)
0.67 (0.57 - 0.79)
0.69 (0.54 - 0.89)

<0.0001

1.0 (ref)
0.61 (0.53 - 0.69)

<0.0001

<0.0001

<0.0001

1.0 (ref)
0.48 (0.42 - 0.55)
1.0 (ref)
0.60 (0.52 - 0.69)

411 (6.39)
1.0 (ref)
<0.0001
89 (2.45) 0.19 (0.13 - 0.27)

1.0 (ref)
0.25 (0.17 - 0.36)

<0.0001

1.0 (ref)

<0.0001

293 (7.7)
152 (3.7)
55 (2.6)

145 (9.32)
1.0 (ref)
355 (4.17) 0.47 (0.42 - 0.53)
33 (13.92)
1.0 (ref)
467 (4.75) 0.36 (0.31 - 0.41)
25 (9.43)
1.0 (ref)
475 (4.85) 0.38 (0.34 - 0.43)

322 (6.85)

1.0 (ref)

<0.0001

<0.0001

<0.0001

<0.0001

0.8849
0.0002

<0.0001

Characteristic
Neuropathy
Cardiovascular
No other ASCVD
Other ASCVD
No other chronic IHD
Other Chronic IHD
Peripheral vascular Disease
No peripheral vascular disease
Peripheral vascular disease

Any “Remission” (n = 500)
Hazard Ratio (95% CI)
n (%)
Unadjusted
P Value
Fully adjusted
178 (3.32) 0.33 (0.28 - 0.41)
0.45 (0.37 - 0.56)
476 (5.49)
1.0 (ref)
24 (1.74) 0.70 (0.52 - 0.95)
340 (5.45)
1.0 (ref)
160 (4.19) 0.83 (0.71 - 0.96)

0.0202
0.0106

380 (5.65)
1.0 (ref)
<0.0001
120 (3.6) 0.53 (0.43 - 0.66)

1.0 (ref)
0.86 (0.62 - 1.19)
1.0 (ref)
1.57 (1.29 - 1.91)
1.0 (ref)
0.85 (0.67-1.07)

Fully adjusted model includes all variables in this table
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*Missing data in No “remission” cohort: race (n = 5), in "remission" cohort: race (n = 1)
If the number of Individuals in a cell was < 10, the number is replaced with “< 10”
Data represented as n (%) for baseline year (2011)

P value

0.3796
<0.0001

0.1625

CONCLUSIONS
Type 2 diabetes mellitus is a progressive chronic disease condition. If left
unmanaged, the body’s ability to regulate blood sugar deteriorates gradually. The
complications associated with dysglycemia can have deleterious effects on the
quality of life of the patient. In order to develop effective intervention programs, it
is first important to understand the prognosis of T2DM. In this regards, the study
presented here investigated two key sub components of T2DM progression: a)
onset of T2DM; b) “remission” of T2DM in a non-bariatric setting.
Using two different study cohorts the study presented here identified key
factors that are associated with T2DM onset and “remission” in Medicare patients
65 years and older. The factors that were significantly associated with T2DM
onset were: male gender; non-white ethnicity (African American, Hispanics);
statin use; hypertension; hyperlipidemia; heart failure; ulcer of lower limbs;
atherosclerosis; other retinopathy; angina pectoris; blindness and low vision;
absence of other chronic ischemic heart disease (IHD) (p<0.05). The factors
associated with T2DM “remission” were no statin use; low diabetes complications
severity index score (DCSI); no hypertension; no hyperlipidemia; no neuropathy;
no retinopathy (p<0.05). Race (Asian/Hispanic); other chronic ischemic heart
disease (IHD); and female gender were significantly associated with T2DM
“remission” (p<0.05).
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The combined results of the onset and “remission” study suggests that
hypertension, hyperlipidemia, statin use, gender, and race are some of the
common factors associated with both T2DM onset and “remission.” Hypertension
and hyperlipidemia are key components of metabolic syndrome. Statins are used
for cardiovascular disease risk reduction in patients with metabolic syndrome
(186). These findings suggest that further investigation in the role of metabolic
syndrome in T2DM progression is warranted for future studies.
This study also found that lower DCSI scores were associated with T2DM
“remission.” This finding can help in stratifying individuals with T2DM into groups
based on their diabetes severity. This information can thus be used for selecting
individuals into disease management programs.
The sociodemographic and clinical profile of Medicare patients 65 years
and older with T2DM onset and T2DM “remission” could be used to: a) educate
T2DM patients, providers, payors and other stakeholders; b) develop T2DM
management programs; c) design public health policies. This will in turn help to
improve quality of life and reduce T2DM disease burden.
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Limitations
There were several limitations to this study as described below.
a) Lack of data: First and most important, the study does not include clinical and
laboratory findings such as physician notes and HbA1c, which would have
provided a more accurate measure of T2DM onset and T2DM remission. This is
especially important in the “remission” cohort because there could be a small
proportion of individuals who were asked by their doctors to stop taking T2DM
medication in order to decrease the stress on the body, or the individual might
have other reasons to stop taking medication, or get prescription samples for
diabetes medication, or pay out of pocket for their T2DM medication. The
probability of not identifying individual’s T2DM status due to these reasons would
be low because even in the absence of pharmacy claims, an individual’s medical
claims are often captured as diagnostic on the medical claims.
Data such as nutrition, physical activity, BMI, original diagnosis date for
T2DM are also not available. The study does not further split the study cohort
based on pre-diabetes and/or undiagnosed individuals.
Individuals with metabolic syndrome cannot be identified due to lack of
data such as BMI and cholesterol data.
b) Coding error: As with other similar retrospective studies there is a potential
for error in the information coded on the administrative data. Even though the
claims are audited on a regular basis there is a possibility of potential for error in
the information coded on medical claims due to provider error, fraud etc.
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c) Causation: As with similar studies, this type of analysis can only establish
associations and is not intended to establish causation of T2DM onset or
“remission”.
d) Complexity: This study is a quasi-experiment (i.e., it’s not a true randomized
study). The factors (covariates, confounding variables, etc.) will not be random
and will not be able to completely eliminate bias or confounding.
e) Dosage of T2DM drug and statin: The level or potency of the T2DM
medications and statins was not evaluated in this analysis.
f) DCSI score: is an unweighted composite index, and does not independently
test individual outcomes associated with each complication associated with
T2DM.
g) Generalizability: The exclusions such as excluding disabled individuals,
excluding individuals with ESRD, excluding individuals with chronic kidney
function in the study cohort limits the generalizability of the study to the overall
Medicare population.
Strengths
The medical and pharmacy data being studied here are part of a
standardized data collection practice of the health insurance organization. The
data is collected using a standardized process with standard protocols for
extraction, transformation and loading (ETL). The data is audited by the
organization for its business purposes and hence less prone to data integrity
issues.
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